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KMV   2-keto-3-methylvalerate 
l   liter 
i.e.   id est (that is) 
L   L-leucine 
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LtbR   leucine and tryptophane biosynthesis regulator 
Lrp   leucine-responsive protein 
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mol   mole 
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n   nano (10-9) 
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NAD(H)  nicotinamide adenine dinucleotide (reduced) 
NADP(H)  nicotinamide adenine dinucleotide phosphate (reduced) 
Ω   ohm 
OD600   optical density at a wavelength of 600 nm 
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P   L-proline 
PCR   polymerase chain reaction 
pH   negative decimal logarithmic value of hydrogen ion concentration 
pO2   oxygen partial pressure 
PTS   phosphotransferase system 
R   L-arginine 
RNA   ribonucleic acid   
rpm   revolutions per minute 
rRNA   ribosomal ribonucleic acid 
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tRNA   transfer ribonucleic acid 
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V   volt 
v/v   volume per volume 
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w/v   weight per volume 
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Summary  
Due to the depletion of fossil energy sources, there is an increasing demand for alternative 
sustainable production processes utilizing renewable resources. Biotechnological 
approaches using microorganisms such as Corynebacterium glutamicum as biocatalysts play 
an important role for the production of beneficial substances. These include the three 
branched-chain amino acids L-valine, L-isoleucine, and L-leucine, as well as their respective 
keto acid precursors, which have diverse commercial applications in food, feed, and 
pharmaceutical industry. In this work, metabolic engineering of the C. glutamicum wild type 
was employed to develop efficient strains for the production of L-leucine and                         
2-ketoisocaproate.  
The key-player enzyme in L-leucine biosynthesis is the leuA-encoded 2-isopropylmalate 
synthase which is feedback-inhibited by low L-leucine concentrations with a Ki of 0.4 mM. A 
feedback-resistant variant of the 2-isopropylmalate synthase was identified and 
characterized biochemically in the available weak L-leucine producer B018, which had been 
obtained by random mutagenesis and screening. The respective gene leuA_B018, devoid of 
the attenuator region and under control of a strong promoter, was integrated in up to three 
copies into the genome of C. glutamicum wild type and combined with additional genomic 
modifications aimed at increasing L-leucine production. These modifications involved              
I) deletion of the gene ltbR encoding the repressor LtbR to increase expression of genes 
leuBCD, II) deletion of the gene iolR encoding the transcriptional regulator IolR to increase 
glucose uptake, III) reduction of citrate synthase activity to increase precursor supply, and  
IV) introduction of a modified ilvN gene encoding a feedback-resistant acetohydroxyacid 
synthase. The production performance of the resulting strains was characterized in shake 
flask and bioreactor cultivations. Under fed-batch conditions, the best producer strain 
accumulated L-leucine to levels exceeding the solubility limit of approximately 24 g l-1. The 
maximal molar product yield and volumetric productivity were 0.30 mol per mol glucose and 
4.3 mmol l-1 h-1, respectively. Moreover, the achieved values were obtained in a defined 
minimal medium with a prototrophic and plasmid-free strain, making this process highly 
interesting for industrial application.  
Based on the described L-leucine producers, strains for the production of the keto acid          
2-ketoisocaproate, the direct precursor of L-leucine, were constructed and characterized as 
well. This was achieved by deletion of the gene encoding the transaminase llvE or 
replacement of the ATG start codon of ilvE by GTG start codon. The resulting strains 
accumulated up to 6.1 g l-1 2-ketoisocaproate in shake flask cultivations, with a molar product 
yield of 0.20 mol per mol glucose and a volumetric productivity of 1.4 mmol l-1 h-1.
2 Zusammenfassung 
Zusammenfassung 
Angesichts knapper werdender fossiler Rohstoffe erlangen alternative nachhaltige  
Produktionsprozesse unter Verwendung erneuerbarer Ressourcen zunehmend an 
Bedeutung. Biotechnologische Ansätze, die Mikroorganismen wie Corynebacterium 
glutamicum als Biokatalysatoren verwenden, spielen dabei eine wichtige Rolle zur 
Produktion nützlicher Substanzen. Hierzu gehören auch die drei verzweigtkettigen 
Aminosäuren L-Valin, L-Isoleucin und L-Leucin und ihre Ketosäure-Vorstufen. Diese 
Substanzen haben verschiedenste Anwendungen in der Nahrungsmittel-, Futtermittel- und 
Pharmaindustrie. Im Rahmen dieser Arbeit wurden, ausgehend vom C. glutamicum-Wildtyp, 
mittels metabolic engineering effiziente Produktionsstämme für L-Leucin und                        
2-Ketoisocaproat entwickelt.  
Das Schlüsselenzym der L-Leucin-Biosynthese ist die 2-Isopropylmalatsynthase, kodiert 
durch das leuA-Gen, die in C. glutamicum durch geringe L-Leucin-Konzentrationen feedback-
inhibiert wird (Ki = 0,4 mM). In einem zur Verfügung stehenden schwachen L-Leucin-
Produzenten B018, der durch Zufallsmutagenese und Screening erhalten worden war, 
konnte eine feedback-resistente Variante der 2-Isopropylmalatsynthase identifiziert und 
biochemisch charakterisiert werden. Das entsprechende Gen leuA_B018 wurde ohne 
Attenuatorregion und unter Kontrolle eines starken Promoters in bis zu drei Kopien in das 
Genom von C. glutamicum eingebracht. Daneben wurden weitere genomische 
Modifikationen durchgeführt, um die L-Leucin-Produktion zu erhöhen: I) Deletion des                
ltbR-Gens für den Repressor LtbR zur Erhöhung der Expression der Gene leuBCD,                     
II) Deletion des iolR-Gens für den Transkriptionsregulator IolR zur Erhöhung der Glucose-
Aufnahmerate, III) Reduktion der Citratsynthase-Aktivität zur Erhöhung der 
Vorstufenbereitstellung, sowie IV) Einführung eines modifizierten ilvN-Gens für eine 
feedback-resistente Acetohydroxysäuresynthase. Die Produktionsleistung der konstruierten 
Stämme wurde in Schüttelkolben und Bioreaktoren charakterisiert. In fed-batch-
Fermentationen akkumulierte der beste Stamm L-Leucin-Konzentrationen über die 
Löslichkeitsgrenze von 24 g l-1 hinaus. Die maximalen Werte für molare Produkt-Ausbeute 
und volumetrische Produktivität betrugen 0,30 mol pro mol Glukose beziehungsweise 
4,3 mmol l-1 h-1. Da diese Werte in definiertem Minimalmedium unter Verwendung eines 
prototrophen und Plasmid-freien Stamms erreicht wurden, ist der beschriebene Prozess sehr 
interessant für die industrielle Anwendung. 
Basierend auf den beschriebenen L-Leucin-Produzenten wurden auch Stämme für die 
Produktion von 2-Ketoisocaproat, der direkten Ketosäure-Vorstufe von L-Leucin, konstruiert 
und charakterisiert. Dazu wurde entweder das Gen für die Transaminase IlvE deletiert oder 
das ATG-Startcodon von ilvE gegen ein GTG-Startcodon ausgetauscht. Mit diesen Stämmen 
konnten bis zu 6,1 g l-1 2-Ketoisocaproat in Schüttelkolben-Kultivierungen produziert werden, 
mit einer molaren Produkt-Ausbeute von 0,20 mol pro mol Glukose und einer volumetrischen 
Produktivität von 1,4 mmol l-1 h-1. 
 
Introduction  3 
1 Introduction 
1.1 Bioeconomy: Sustainable production processes using renewable 
resources 
In times of the depletion of fossil energy sources, society is facing steadily increasing oil and 
gas prices, proceeding environmental pollution, and climate change. In addition, the rapid 
growth of the world population increases the demand for energy, which will further 
exacerbate the economic and social challenges in the near future. Therefore, the focus of 
bulk and fine chemical production is shifting more and more from products based on fossil 
fuels to production processes using renewable resources. Bioeconomy strategies have been 
elaborated in different nations and regions, i.e. the USA and European Union (Philp et al., 
2013). The term “bioeconomy” comprises the efforts to create sustainable economic growth 
based on renewable and environmentally friendly products. Biotechnology, especially white 
biotechnology, is expected to take a major part in this development with biotransformations 
and fermentations (Octave and Thomas, 2009).  
As an alternative to classical chemical synthesis processes, biotechnology offers 
applications for the ecological and economic valuable production of bulk chemicals, i.e. fuels, 
solvents, plastics, etc., from renewable plant biomass. Microorganisms are employed as 
biocatalysts in fermentation processes to produce beneficial substances such as amino 
acids, organic acids, alcohols, vitamins, or antibiotics in an efficient and cost-effective 
manner (Wendisch et al., 2006a). The market share of biotechnological products concerning 
bio-based chemicals is expected to grow worldwide from currently 9-13% to 22-28% in 2025 
(Kircher, 2012).  
Due to its economic and ecological advantages in comparison to chemical methods such 
as synthesis and extraction, the biotechnological production of amino acids has shown a 
rapid development and represents one of the most important categories of fermentation 
products (Leuchtenberger et al., 2005). To establish optimized, economic, and competitive 
biotechnological processes, factors like bioreactor design, optimization of yields, reduction of 
process times, and downstream processing have to be addressed. Especially the latter point 
dealing with extraction and purification of the desired products is a very important factor 
(Schügerl and Hubbuch, 2005). Nevertheless, suitable production strains with desired 
properties for the respective substances to be produced are absolutely crucial and represent 
the core of fermentation processes (Hermann, 2003). Therefore, strain development for 
biotechnological purposes has a long tradition. Besides Escherichia coli, 
Corynebacterium glutamicum is one of the most important bacteria used in industrial 
biotechnology. 
4 Introduction 
1.2 Biotechnological relevance of C. glutamicum and applications of 
branched-chain amino acids 
C. glutamicum, a gram-positive soil bacterium, has become a platform organism in industrial 
biotechnology, especially for the production of amino acids. Its biosynthesis capacities and 
its GRAS (“generally recognized as safe”) status make it an ideal host for the effective and 
safe production of a wide variety of compounds. C. glutamicum is able to grow on diverse 
renewable carbon sources as feedstock. In particular, sugars from agricultural crops such as 
cane molasses, beet molasses, as well as starch molasses from corn and cassava are used 
in industrial fermentations (Ikeda, 2012). Feedstock variability is an important economic 
factor since market prices of carbon sources are highly volatile (Kircher, 2012). To broaden 
the substrate spectrum, efforts are being made to engineer C. glutamicum for the utilization 
of alternative feedstock, i.e. starch, hemicellulose, and glycerol (Becker and Wittmann, 
2012a; Wendisch et al., 2006a). Since the genome of C. glutamicum is known (Ikeda and 
Nakagawa, 2003; Kalinowski et al., 2003) and efficient techniques for its genetic engineering 
exist (Binder et al., 2013; Kirchner and Tauch, 2003), the creation of tailor-made strains with 
desired properties is feasible. Moreover, this microorganism has additional advantages in 
comparison to other hosts: For example, the reduced abundance of isoenzymes enables 
efficient metabolic flux control. This and the increased phage-resistance as compared to 
E.coli make C. glutamicum an ideal candidate for engineering and production. Moreover, no 
deleterious accumulation of acetic acid occurs and the reduced presence of degradative 
enzymes for amino acids facilitates efficient production of these substances (Eggeling et al., 
1997).  
C. glutamicum is mainly used to produce several million tons of amino acids annually, with 
the flavor enhancer L-glutamate (2,400,000 tons/year) and the feed additive L-lysine 
(1,500,000 tons/year) as major products (Becker and Wittmann, 2012b). Three 
comprehensive monographs (Burkovski, 2008; Eggeling and Bott, 2005; Yukawa and Inui, 
2013) depict the increasing knowledge obtained about this bacterium. Apart from amino 
acids, strains have also been developed for the production of other commercially interesting 
compounds (Becker and Wittmann, 2012a), such as organic acids (Litsanov et al., 2012a, 
2012b; Okino et al., 2008; Wieschalka et al., 2013), diamines (Kind and Wittmann, 2011; 
Mimitsuka et al., 2007; Schneider and Wendisch, 2011), or alcohols (Blombach et al., 2011; 
Inui et al., 2004; Smith et al., 2010;). Moreover, also the production of heterologous proteins 
is possible using this host (Scheele et al., 2013, and references therein).  
Besides the major products L-glutamate and L-lysine, C. glutamicum can also be used for 
the production of many other amino acids. These include also the group of branched-chain 
amino acids (BCAAs), i.e. L-valine, L-isoleucine, and L-leucine. These amino acids have a 
small but substantially growing market of up to 5,000 tons per year (Becker and Wittmann, 
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2012b). BCAAs are the most abundant of the essential amino acids, are hydrophobic due to 
their unsubstituted aliphatic chains with branched alkyl groups (Figure 1), and have diverse 
applications (Pátek, 2007, Yoshizawa, 2012). They are used as components of 
pharmaceuticals and cosmetics, in the animal feed industry, as dietary products, and as 
precursors in the chemical synthesis of herbicides (Park and Lee, 2010a). BCAAs are used, 
for example, in the medical treatment of patients with hepatic diseases to improve the 
nutritional status (Freund et al., 1982). They are absolutely essential for immune cell 
functions such as lymphocyte responsiveness (Calder, 2006). During endurance sports 
events, these amino acids, particularly L-leucine, attenuate the breakdown of muscle 
proteins, promote protein synthesis in skeletal muscle, and prevent premature muscle fatigue 
(Rennie et al., 2006; Shimomura et al, 2006). Therefore, BCAAs are used as special dietary 
supplements in sports nutrition because they are expected to promote maintaining and 
regeneration of the skeletal muscle (Pátek, 2007). L-isoleucine is particularly used in the food 
and feed industry (Morbach et al., 2000). Studies showed that L-isoleucine stimulates 
glucose uptake in the muscle, promotes whole body oxidation, and derepresses 
gluconeogenesis (Yoshizawa, 2012). L-Valine has applications also as feed additive and 
precursor for the chemical synthesis of herbicides (Eggeling, 1996; Leuchtenberger, 1996). 
The BCAA L-leucine is the focus of this work. Together with L-valine and L-isoleucine, it is 
used as a component of infusion solutions and special dietary products (Eggeling et al., 
1997). L-Leucine plays a potent role in the stimulation of muscle protein synthesis, while the 
other BCAAs are less effective, and mechanisms for its signaling action are discussed in the 
literature (Garlick, 2005; Yoshizawa, 2012). Also the effect of this amino acid on glucose 
homeostasis has been investigated (Layman, 2003). L-Leucine is also applied as a flavoring 
substance and as a lubricant for tablet production (Leuchtenberger, 1996; Rotthäuser et al., 
1998). 
The direct keto acid precursors of L-valine, L-isoleucine, and L-leucine are                               
2-ketoisovalerate (KIV), 2-keto-3-methylvalerate (KMV), and 2-ketoisocaproate (KIC), 
respectively (Figure 1). These keto acids also have a variety of applications similar to their 
corresponding BCAAs in the medical, biological, and food area since they play an important 
role in living organisms as regulation factors in metabolism and key intermediates of 
biosynthesis (Bückle-Vallant et al., 2014; Krause et al., 2010; Zhu et al., 2011). They are, for 
example, used in the therapy of chronic kidney disease patients (Aparicio et al., 2012). KIC 
has similar effects as its corresponding amino acid L-leucine because it has anti-catabolic 
properties through inhibition of muscle proteolysis and provokes enhancement of protein 
synthesis, especially in the skeletal muscle (Escobar et al., 2010; Zanchi et al., 2011). Also, 
an insulin-releasing action of KIC (Heissig et al., 2005) and its inhibitory effect on glucagon 
release (Leclercqmeyer et al., 1979) have been discussed. Furthermore, the use of KIC and 
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the other keto acids as precursors for other interesting products is feasible. For example, it 
was shown that KIC can serve as a basis for the production of the biofuel isopentanol                 
(3-methyl-1-butanol) (Cann and Liao, 2010). Until now, KIV, KMV, and KIC are mainly 
produced by chemical synthesis, using harsh reaction conditions and multiple purification 
steps (Cooper et al., 1983), but first microbial producers for KIV and KIC have been reported 
recently (Bückle-Vallant et al., 2014; Krause et al., 2010). 
All these mentioned aspects provide promising applications. Therefore, BCAAs and their 
keto acid precursors are interesting products of industrial fermentations. In order to 
understand the processes that lead to the accumulation of these compounds in production 
strains, detailed knowledge of their biosynthesis pathways is necessary. 
 
 
 
 
 
 
 
Figure 1. The three proteinogenic branched-chain amino acids L-valine (A),                    
L-isoleucine (B), and L-leucine (C), as well as their respective keto acid precursors               
2-ketoisovalerate (D), 2-keto-3-methylvalerate (E), and 2-ketoisocaproate (F). 
 
 
1.3  Biosynthesis of BCAAs and its regulatory mechanisms in 
C. glutamicum 
The biosynthesis pathways of the BCAAs (Figure 2) are overlapping and interrelated since 
they are characterized by homologous reactions catalyzed by single enzymes, branch points, 
as well as multivalent regulation of both gene expression and enzyme activity (Pátek, 2007).  
 
A) B) C) 
D) E) F) 
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Figure 2. The biosynthetic pathways of BCAAs, as well as corresponding regulation 
mechanisms and transport systems involved in C. glutamicum (taken and modified 
from Park and Lee, 2010a).                                                                                                                                                
Dashed lines indicate feedback-inhibition. The thick dashed lines indicate transcriptional 
attenuation regulation. Gray lines indicate regulation of gene expression by Lrp and LtbR; “+” 
and “-“ indicate activation and repression of gene expression, respectively. The avtA gene 
encoding the transaminase AvtA (Marienhagen et al., 2005) is not depicted. 
 
As the first step in the biosynthesis of L-valine and L-leucine in C. glutamicum, two 
molecules of pyruvate are converted to 2-acetolactate by the enzyme acetohydroxyacid 
synthase (AHAS), encoded by the genes ilvB (coding for the catalytic subunit) and ilvN 
(coding for the regulatory subunit). 2-Acetolactate is further metabolized to                               
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2,3-dihydroxyisovalerate and 2-ketoisovalerate (KIV) by the enzymatic activities of                    
ilvC-encoded acetohydroxyacid isomeroreductase (AHAIR) and ilvD-encoded dihydroxyacid 
dehydratase (DHAD), respectively (Cordes et al., 1992; Keilhauer et al., 1993; Radmacher et 
al., 2002). The genes ilvB, ilvN and ilvC are organized as an operon and their expression is 
controlled by a transcriptional attenuation mechanism mediated by all three BCAAs (Morbach 
et al., 2000). In parallel reactions, AHAS, AHAIR, and DHAD also catalyze the subsequent 
formation of 2-aceto-2-hydroxybutyrate, 2,3-dihydroxy-3-methylvalerate, and finally                         
2-keto-3-methylvalerate (KMV) from pyruvate and 2-ketobutyrate. The latter substrate is 
formed by action of ilvA-encoded threonine dehydratase from L-threonine. This is the only 
enzyme specific for L-isoleucine biosynthesis and exhibits allosteric feedback-inhibition by                          
L-isoleucine (Cordes et al., 1992, Möckel et al., 1992). It was shown that the enzymatic 
activity of AHAS is inhibited by any of the three branched-chain amino acids (Eggeling et al., 
1987), but inhibition of AHAS does not exceed 57%, even in the presence of all three BCAAs 
(Elišáková et al., 2005). The half maximal inhibitory concentration (IC50) values of AHAS for 
L-valine, L-isoleucine, and L-leucine are 0.9 mM, 3.1 mM, and 6.0 mM, respectively 
(Leyval et al., 2003). KMV is transaminated to L-isoleucine by transaminase IlvE. KIV is 
transaminated to L-valine by IlvE, but also by the transaminase AvtA (Marienhagen et al., 
2005; Marienhagen and Eggeling, 2008).  
Furthermore, KIV is a precursor for D-pantothenate biosynthesis and a substrate of the             
2-isopropylmalate synthase (IPMS). This enzyme encoded by leuA represents the first step 
in the specific L-leucine-biosynthesis pathway (Pátek et al., 1994). Gene leuA is controlled by 
an attenuation mechanism which reduces expression to approximately 50% in the presence 
of L-leucine. In addition, IPMS underlies the control of a strong feedback-inhibitory 
mechanism by L-leucine (Ki = 0.4 mM) (Mentz et al., 2013; Pátek et al., 1994). This enzyme 
synthesizes 2-isopropylmalate from one molecule of KIV and one molecule of acetyl-CoA. 
Subsequently, 2-isopropylmalate is converted to 3-isopropylmalate and finally to the direct               
L-leucine precursor KIC. This is performed by the enzymatic activities of 3-isopropylmalate 
dehydratase (IPMD) and 3-isopropylmalate dehydrogenase (IPMDH), which are encoded by 
leuCD and leuB, respectively (Pátek et al., 1994). Both leuCD and leuB are repressed by the 
IclR-type transcriptional regulator LtbR (leucine and tryptophane biosynthesis regulator) in 
response to L-leucine (Brune et al., 2007). Eventually, KIC is transaminated to L-leucine by 
the transaminase IlvE. Besides that, other transaminases such as the aroT-encoded 
aromatic amino acid transaminase exhibit weak side activities for the transamination of KIC 
to L-leucine (Marienhagen et al., 2005).   
All three BCAAs as well as L-methionine are excreted by a two component permease of 
the LIV-E family, encoded by brnFE (Kennerknecht et al., 2002). Expression of brnFE is 
thereby activated via the transcriptional regulator Lrp (leucine-responsive protein) by the 
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BCAAs and L-methionine, but mainly in the presence of elevated intracellular L-leucine 
concentrations (Lange et al., 2012). The transporter encoded by brnQ imports all three 
BCAAs (Tauch et al., 1998). 
 
1.4 C. glutamicum strains for the production of BCAAs and their keto acid 
precursors: Metabolic engineering as an alternative to random 
mutagenesis 
Production strains of C. glutamicum and E. coli for BCAAs have been developed based on 
random mutagenesis, but also strains exist that have been constructed by targeted metabolic 
engineering (Park and Lee, 2010a). Effective strains have already been created from the 
C. glutamicum wild type for production of BCAAs, which is less the case for E. coli, and this 
work will also focus on C. glutamicum. The classical approach to generate microbial 
producers comprises random mutagenesis and selection procedures until strains are 
obtained exhibiting desired yield and productivity. This strategy created potent production 
strains for all three BCAAs in the past (Park and Lee, 2010a). Nevertheless, random 
mutagenesis has serious drawbacks: Random distributions of mutations not related to the 
targeted pathway can cause undesired changes in cell physiology, e.g. high by-product 
accumulation and growth retardation. Moreover, “dead-end” mutants are often produced 
which cannot be improved further (Park and Lee, 2010b). In contrast to this, rational 
metabolic engineering offers the possibility to create genetically defined strains. 
Disadvantages of the classical approaches can be prevented and desired properties, e.g. 
prevention of auxotrophies, can be directly addressed. Nevertheless, strains obtained by 
undirected mutagenesis offer a rich source of mutations which increase product formation 
and therefore are used in metabolic engineering (Ikeda et al., 2006) (Figure 3). 
Using recombinant DNA technology, metabolic engineering is defined as the direct 
improvement of cellular properties through modification of specific biochemical reactions 
(Stephanopoulos, 1999). This includes the targeted amplification or deletion of DNA 
sequences as well as the modulation and deregulation of gene expression or enzyme 
activity. In this manner, carbon flux is optimally directed to the formation of the target 
metabolite in order to achieve yields near the theoretical maximum values (Park and Lee, 
2010b). In the case of the production of BCAAs, their interrelated biosynthesis (section 1.3) 
makes metabolic engineering particularly challenging. Modifications in one BCAA pathway 
can easily lead to detrimental effects in the other pathways or to large accumulation of by-
products, which would negatively affect yield and downstream processing. Selected existing 
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strains for the production of the three BCAAs and their keto acid precursors are described in 
this section and comprise different metabolic engineering strategies, such as amplification or 
deletion of target genes, modulation of gene expression via promoter exchange, and 
elimination of regulatory mechanisms.  
For L-valine production, suitable strains of Brevibacterium lactofermentum, which was 
later renamed into C. glutamicum (Liebl et al., 1991), were achieved by random mutagenesis 
(Tsuchida et al., 1975). There are also several C. glutamicum strains that have been 
constructed rationally. The first rationally designed strain was reported by Radmacher et al. 
(2002). In this strain, deletion of the genes panBC, involved in the formation of                           
D-pantothenate from KIV, and deletion of ilvA, together with plasmid-borne overexpression of 
ilvBNCD, led to L-valine accumulation. Blombach et al. (2007) achieved L-valine production 
by deleting the aceE gene coding for E1p enzyme of the pyruvate dehydrogenase complex 
(PDHC) and plasmid-based overexpression of ilvBNCE. This strain was improved by 
additional deletion of pqo, encoding pyruvate:quinone oxidoreductase, and pgi, encoding 
phosphoglucose isomerase (Blombach et al., 2008). A similar improved strain was obtained 
by downregulation of aceE expression via promoter exchange in a Δpqo Δppc (the latter 
encoding phosphoenolpyruvate carboxylase) background and plasmid-based overexpression 
of ilvBNCE (Buchholz et al., 2013). Besides overexpressing ilvBNC on a plasmid in a ΔilvA 
ΔpanB strain, Elišáková et al. (2005) made use of an ilvN allele (ilvNM13) resulting in an 
AHAS variant that is feedback-resistant for all three BCAAs. 
For L-isoleucine production, Kase and Nakayama (1977) reported a C. glutamicum strain 
that was obtained by a classical random mutagenesis approach based on an L-threonine-
producer, but also rationally designed strains exist. Using a C. glutamicum L-lysine producer 
with feedback-resistant aspartate kinase, encoded by lysC(fbr), L-isoleucine accumulation 
was achieved by three hom(fbr) copies, encoding feedback-resistant homoserine 
dehydrogenase, and ilvA(fbr), encoding feedback-resistant threonine dehydratase, on a 
multicopy plasmid (Morbach et al., 1995). In a subsequent study, transport of L-isoleucine 
was identified as a major limiting step for the production of this amino acid (Morbach et al. 
1996). Indeed, Xie et al. (2012) showed that deletion of the brnQ-encoded BCAA importer 
and, more importantly, overexpression of the brnFE-encoded BCAA exporter increased                
L-isoleucine production in the C. glutamicum strain YILW. Plasmid-based co-expression of a 
feedback-resistant threonine dehydratase and acetohydroxyacid synthase in C. glutamicum 
JHI3-156 led to an increase of L-isoleucine production (Yin et al., 2012). 
Only a few studies deal with the microbial production of L-leucine using either 
B. lactofermentum (respectively C. glutamicum) or E. coli as hosts (Park and Lee, 2010a). All 
C. glutamicum-based production strains were created by random mutagenesis: One of the 
first L-leucine producers was a 2-thiazolealanine-resistant, methionine-isoleucine-auxotrophic 
Introduction  11 
mutant derived from the L-glutamic acid producing B. lactofermentum 2256 by 
nitrosoguanidine treatment (Tsuchida et al., 1974). The productivity of this strain was further 
optimized by additional mutagenesis steps (Ambe-Ono et al., 1996; Tsuchida and Momose, 
1986). Another S-(2-aminoethyl)-L-cysteine-resistant mutant was derived from 
C. glutamicum ATCC 13032 (Azuma et al., 1987).  
Besides a described biotransformation with Rhodococcus opacus using L-leucine as 
substrate for the production of KIC (Zhu et al., 2011), first C. glutamicum strains for the 
production of KIV and KIC have been described recently in the literature. A first KIV 
producing C. glutamicum strain was achieved by deleting the genes aceE, ilvE, and pqo and 
plasmid-based overexpression of ilvBNCD (Krause et al., 2010). Based on this work, an 
improved producer of KIV was constructed by downregulating the activity of the aceE 
promoter in a ΔilvE Δpqo Δppc strain background and additional plasmid-based 
overexpression of ilvBNCD (Buchholz et al., 2013). Very recently, Bückle-Vallant and 
colleagues (2014) designed a C. glutamicum strain for the production of KIC. They 
downregulated the activity of citrate synthase via a promotor exchange based on a promoter 
originally used to improve L-lysine synthesis (van Ooyen et al., 2012). Furthermore, this 
strain is characterized by deletions of the genes ilvE, ltbR, prpC1, and prpC2 (the latter two 
encoding methylcitrate synthases) as well as plasmid-based overexpression of ilvBNCD and 
a leuA allele from E. coli encoding a feedback-resistant 2-isopropylmalate synthase. 
 
 
 
 
 
 
 
 
 
Figure 3. Strain development by random mutagenesis/selection and targeted 
metabolic engineering (from Park and Lee, 2008, modified).                                                                                                                                                 
The classical method of strain development comprises random mutagenesis with subsequent 
selection procedures. This strategy is repeated until the desired properties, such as high 
product titers, are achieved. Alternatively, targeted metabolic engineering of genes and 
biosynthesis pathways has become a standard strategy for strain development. The 
combined use of random and directed approaches is recognized as an efficient method for 
strain construction (Klein-Marcuschamer and Stephanopoulos, 2010). 
12 Introduction 
1.5 Aims of this work  
This work describes the rational design and construction of C. glutamicum L-leucine 
production strains by targeted metabolic engineering starting from the wild-type strain. The 
aim was to design genetically defined producers that reach high values in terms of product 
titer, yield, and productivity. Moreover, the created strains should be devoid of auxotrophies, 
plasmids and heterologous genes. Auxotrophies have the disadvantage that supplements 
have to be added to the fermentation medium in order to allow microbial growth, which 
increases costs of the fermentation process. Due to their antibiotic resistance markers, the 
industrial application of plasmids in genetically engineered production strains in food and 
feed industry can be resisted by regulatory agencies (Tauch et al., 2002). This is also true for 
the use of heterologous genes, which are not accepted by the society in large-scale 
fermentations. Besides that, the absence of plasmids, markers, and heterologous genes 
often provides more stable producer strains (Pátek, 2007). Addressing all these aspects was 
supposed to facilitate a direct use of the constructed strains for industrial fermentation 
processes. The single metabolic steps should be analyzed and discussed concerning their 
effects on L-leucine production and strategies should be developed for further strain 
improvement. Moreover, possibilities of turning existing L-leucine producers into producers 
for the precursor 2-ketoisocaproate, which also has interesting commercial applications, 
were addressed. 
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2 Material and Methods  
2.1 Bacterial strains and plasmids 
All bacterial strains and plasmids used in this work as well as their relevant characteristics 
are listed in Table 1 and Table 2, respectively.  
Plasmid-based gene expressions were achieved using vector pAN6 carrying an IPTG-
inducible tac promoter (Frunzke et al., 2008) or derivatives of pJC1 (Cremer et al., 1990).  All 
marker-free in-frame deletions and integrations of DNA sequences in C. glutamicum strains 
were done via two-step homologous recombination using vector pK19mobsacB (Schäfer et 
al., 1994). Plasmid constructions are described in section 2.5.14. 
 
 
Table 1. Bacterial strains used in this work. 
Strain Relevant characteristics Source or 
reference 
C. glutamicum 
strains 
  
Wild type wild type ATCC 13032 (biotin auxotrophic) Abe et al. 
(1967) 
B018 L-leucine producing C. glutamicum strain created 
by random mutagenesis 
Amino GmbH, 
Frellstedt, 
Germany 
ΔltbR                      ATCC 13032 derivative with in-frame deletion of 
ltbR                                                                                                                            
This work 
ΔltbR  ΔleuA C. glutamicum ΔltbR derivative with in-frame 
deletion of leuA along with its 180 bp upstream 
region                                                                                                                                             
This work 
ΔltbR ilvN_fbr C. glutamicum ΔltbR derivative with 
chromosomally integrated mutations into ilvN 
coding for amino acid exchanges G20D, I21D, 
and I22F 
This work 
ΔilvE ATCC 13032 derivative with in-frame deletion of 
ilvE                                                                                                                            
Marienhagen et 
al. (2005)        
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Strain Relevant characteristics Source or 
reference 
   
MV-Leu7 C. glutamicum ΔltbR derivative with a mutated 
leuA gene encoding the amino acid exchanges 
R529H and G532D (leuA_B018) in comparison to 
the wild-type leuA                  
This work 
MV-Leu20 C. glutamicum ΔltbR ΔleuA derivative with 
chromosomal integration of leuA from B018 under 
control of the tuf promoter into the ΔleuA locus 
This work 
MV-Leu20 
ΔltbR::Ptuf-
leuA_B018 
MV-Leu20 derivative with chromosomal 
integration of a second copy of leuA from B018 
under control of the tuf promoter into the ΔltbR 
locus 
This work  
MV-ValLeu33 MV-Leu20 derivative with chromosomally 
integrated mutations into ilvN coding for amino 
acid exchanges G20D, I21D, and I22F 
This work 
MV-Leu55  MV-Leu20 ΔltbR::Ptuf-leuA_B018 derivative with 
chromosomally integrated mutations into ilvN 
coding for amino acid exchanges G20D, I21D, 
and I22F 
This work 
MV-Leu55 ΔbrnQ MV-Leu55 derivative with in-frame deletion of 
brnQ 
This work 
MV-Leu55 ΔavtA MV-Leu55 derivative with in-frame deletion of 
avtA 
This work 
MV-Leu55 ΔiolR MV-Leu55 derivative with in-frame deletion of  
iolR 
This work 
MV-Leu55 Δcg3022 MV-Leu55 derivative with in-frame deletion of  
cg3022 
 
 
This work 
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Strain Relevant characteristics Source or 
reference 
   
MV-LeuF1 MV-Leu55 ΔiolR derivative with chromosomal 
integration of a third copy of leuA from B018 
under control of the tuf promoter integrated into 
the intergenic region between cg1121 and cg1122 
This work 
MV-LeuF2 MV-LeuF1 derivative with chromosomal 
replacement of the gltA promoter by dapA-L1 
promoter 
This work 
MV-KICF1 MV-LeuF1 derivative with chromosomal 
replacement of the ATG start codon of ilvE by 
GTG start codon 
This work 
SH-KIC20 MV-Leu20 derivative with chromosomal 
replacement of the ATG start codon of ilvE by 
GTG start codon 
Sabine Haas 
(FZ Jülich, 
Germany) 
E. coli strains   
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 
endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 
gyrA96 relA1 
Invitrogen 
(Karlsruhe, 
Germany) 
 
 
Table 2. Plasmids used in this work. 
Plasmid Relevant characteristicsa Source or 
reference 
 
pAN6 
 
Kanr; E. coli/C. glutamicum shuttle vector for 
inducible gene expression (Ptac, lacIq, pUC18 
oriVE.coli, pBL1 oriVC.glutamicum) 
 
Frunzke et al. 
(2008) 
pAN6-leuA_wt Kanr; pAN6 derivative containing the leuA gene 
from  C. glutamicum wild type under control of the 
tac promoter 
This work 
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Plasmid Relevant characteristicsa Source or 
reference 
 
pAN6-leuA_B018 
 
Kanr; pAN6 derivative containing the leuA gene 
from  B018 under control of the tac promoter 
 
This work 
pAN6-leuA_mod Kanr; pAN6 derivative containing the leuA_mod 
gene under control of the tac promoter 
This work 
pK19mobsacB Kanr; vector for allelic exchange in C. glutamicum 
(pK18 oriVE.coli, sacB, lacZα) 
Schäfer et al. 
(1994) 
pK19mobsacB- 
leuA_B018_BS 
Kanr, pK19mobsacB derivative containing a             
1378 bp overlap-extension PCR product 
(SbfI/XbaI) which covers the partial sequence of 
leuA from B018 coding for the amino acid 
exchanges R529H and G532D flanked by its 
upstream and downstream regions 
(approximately 560 bp and 810 bp, respectively) 
This work 
pK19mobsacB- 
ΔleuA  
Kanr, pK19mobsacB derivative containing a            
1060 bp overlap-extension PCR product (flanking 
SbfI/XbaI and intrinsic NdeI/MluI/SpeI restriction 
sites) which covers the flanking upstream and 
downstream regions (approximately 490 bp and 
550 bp, respectively) of the leuA gene along with 
its 180 bp upstream region 
This work 
pK19mobsacB-Ptuf-
leuA_B018 
Kanr, pK19mobsacB-ΔleuA derivative containing 
the leuA gene from B018 (MluI/SpeI) under 
control of the tuf promoter (NdeI/MluI) flanked by 
upstream and downstream regions of leuA  
This work 
pK19mobsacB-ΔltbR Kanr, pK19mobsacB derivative for in-frame 
deletion of gene ltbR 
Jan van Ooyen 
(FZ Jülich, 
Germany) 
pK19mobsacB-ΔilvE Kanr, pK19mobsacB derivative for in-frame 
deletion of gene ilvE 
 
Marienhagen et 
al. (2005) 
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Plasmid Relevant characteristicsa Source or 
reference 
 
pK19mobsacB- 
ΔltbR::Ptuf-
leuA_B018 
 
Kanr, pK19mobsacB-ΔltbR derivative containing 
the leuA gene from B018 under control of the tuf 
promoter along with the 70 bp upstream region of 
leuA (AvrII) covered by upstream and 
downstream regions of ltbR 
 
This work 
pK19mobsacB-
ilvN_fbr 
Kanr, pK19mobsacB derivative containing a             
1279 bp overlap-extension PCR product 
(SbfI/XbaI) which covers the partial sequence of 
ilvN coding for the amino acid exchanges G20D, 
I21D, and I22F flanked by its upstream and 
downstream regions (approximately 620 bp and 
660 bp, respectively) 
This work 
pK19mobsacB- 
ΔbrnQ 
Kanr, pK19mobsacB derivative for in-frame 
deletion of gene brnQ 
Kennerknecht 
(2003) 
pK19mobsacB- 
ΔavtA  
Kanr, pK19mobsacB derivative for in-frame 
deletion of gene avtA  
Marienhagen et 
al. (2005) 
pK19mobsac- 
ΔiolR2 
Kanr, pK19mobsacB derivative for in-frame 
deletion of gene iolR 
Klaffl et al. 
(2013) 
pK19mobsac- 
ΔPgltA::PdapA-L1 
Kanr, pK19mobsacB derivative for chromosomal 
replacement of the gltA promoter by dapA-L1 
promoter 
van Ooyen et 
al. (2012) 
pK19mobsac- 
Δcg3022 
Kanr, pK19mobsacB derivative containing a 
1171 bp overlap-extension PCR product  
(SbfI/EcoRI) which covers the flanking upstream 
and downstream regions (approximately 570 bp 
and 510 bp, respectively) of gene cg3022  
 
 
 
This work 
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Plasmid Relevant characteristicsa Source or 
reference 
 
pK18mobsac-
lysOP7 
 
Kanr, contains artificial operon integrated into the 
intergenic region between cg1121 and cg1122 
(pK18 oriVE.coli, sacB, lacZα);                               
synonym: pK18mobsacB NCR1/ dapA-dapB-asd-
lysA-ddh /NCR2 
 
Blombach et al. 
(2009) 
pK18mobsacB-Ptuf- 
leuA_B018 
Kanr, pK18mobsac-lysOP7 derivative containing 
the leuA gene from B018 under control of the tuf 
promoter along with the 54 bp downstream region 
of leuA (XhoI/EcoRI) integrated into the intergenic 
region between cg1121 and cg1122 
This work 
pK19mobsacB- 
GTG-ilvE 
Kanr, pK19mobsacB derivative for replacement of 
the ATG start codon of ilvE by GTG start codon 
Haas (2013) 
pJC1 Kanr; E. coli/C. glutamicum shuttle vector 
(oriVE.coli, oriVC.glutamicum) 
Cremer et al. 
(1990) 
pJC1-leuCD Kanr, pJC1 derivative containing genes leuC and 
leuD 
Karin Krumbach 
(FZ Jülich, 
Germany) 
pJC1-leuB Kanr, pJC1 derivative containing gene leuB Karin Krumbach 
(FZ Jülich, 
Germany) 
pJC1-ilvE Kanr, pJC1 derivative containing gene ilvE Karin Krumbach 
(FZ Jülich, 
Germany) 
pJC1-brnFE Kanr, pJC1 derivative containing genes brnF and 
brnE 
Kennerknecht 
et al. (2002) 
a Kanr; kanamycin resistance 
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2.2 DNA oligonucleotides 
All DNA oligonucleotides used in this work, as well as their sequence and introduced 
recognition sites for restriction enzymes, are listed in Table 3. They were used for plasmid 
constructions, sequencing reactions, and confirmation of proper integration or deletion of 
DNA sequences in the chromosome of C. glutamicum. All DNA oligonucleotides were 
synthesized by Eurofins MWG Operon (Ebersfeld, Germany). 
 
Table 3. DNA oligonucleotides used in this work. 
Name DNA Sequence (5´- 3´)a Restriction  
sites 
Oligonucleotides for plasmid constructions 
NdeI_leuA_B018_Fw AAACATATGTCTCCTAACGATGCATTCATCTC
CGCACCTGCCAAG 
NdeI 
leuA_ASAustausch_Fw CGCGACAACGACCCACTGACCGCTTACGCCA
AC 
- 
leuA_ASAustausch_Fw AGCGGTCAGTGGGTCGTTGTCGCGGCCATC - 
EcoRI_leuA_B018_Rev TTTGAATTCTTAAACGCCGCCAGCCAGGACTG
CCTCGTGGTTGACGTCC 
EcoRI 
Sbf1_leuA_B018_intern_
Fw 
AAAACCTGCAGGACCGTTGAATACTGCAACC
AGCTGCGCG 
SbfI 
XbaI_leuA_int_down_ 
Rev 
TTTTTCTAGACCTCAATAGCTTCTTGGCGCTC
AGCTTCGATTC 
XbaI 
SbfI_leuA_int_up_Fw AAAACCTGCAGGGCGGAATACGTATTAAAGA
AGGACAAAGCCCTC 
SbfI 
NdeI-MluI-SpeI-
leuA_int_Fw 
CATATGGGAACGCGTGGAACTAGTGCTTTAC
GACGCCTCCCCCTAG 
NdeI, MluI, 
SpeI 
NdeI-MluI-SpeI-
leuA_int_Rev 
ACTAGTTCCACGCGTTCCCATATGGAGTTTTC
TTTTAAAAAAGCTTTTCG 
NdeI, MluI, 
SpeI 
leuA_B018_amp_Fw AAAACGCGTATGTCTCCTAACGATGCATTCAT
CTCCGCACCTGCCAAG 
MluI 
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Name DNA Sequence (5´- 3´)a Restriction 
sites 
 
leuA_B018_amp_Rev 
 
TTTACTAGTTTAAACGCCGCCAGCCAGGACTG
CCTCGTGGTTGACGTCC 
 
SpeI 
NdeI_Peftu_Fw  GGGGCATATGCCACAGGGTAGCTGGTAGTTT
GAAAATC 
NdeI 
MluI_Peftu_Rev AAAAACGCGTTCCTCCTGGACTTCGTGGTGG
CTAC  
MluI 
AvrII_Peftu_Fw   GGGGCCTAGGCCACAGGGTAGCTGGTAGTTT
GAAAATC 
AvrII 
AvrII_leuA_Rev  
 
AAACCTAGGCGGTGGCAAGAATTTTCAACATC
GTGGAATTCTTGCCACCGGTTTGTAGAGGCT
AGGGGG 
AvrII 
XhoI-Peftu_Fw  AAAACTCGAGCCACAGGGTAGCTGGTAG XhoI 
EcoRI-leuA_Rev  GGGGAATTCTTGCCACCGGTTTGTAGAG EcoRI 
SbfI_ilvN_up_Fw   AAAACCTGCAGGGCCCTTGGAGCAAAGGCTG SbfI 
XbaI_ilvN_down_Rev   GGGGTCTAGAGCAGTTCAATAGCCATGGGAG XbaI 
SOE_ilvN_Fw  GACGTAGACGATGACTTTTCCCGCGTATCAG
GTATGTTCAC 
- 
SOE_ilvN_Rev  CGGGAAAAGTCATCGTCTACGTCCTGAACGA
GTACGGAC 
- 
SbfI_AcT_Fw  AAAACCTGCAGGCTGCGTACGAGGGCAAGGA
TCTTGTCAC 
SbfI 
EcoRI_AcT_Rev GGGGGAATTCGCACCCAGAAAAAACCAATGC
CAGGTAC 
EcoRI 
SOE_AcT_Fw  ACCCGTCACTCCACCATCTCCGCTGCTTCCG
CAATGAGCTC 
 
- 
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Name DNA Sequence (5´- 3´)a Restriction 
sites 
 
SOE_AcT_Rev  
 
GCTCATTGCGGAAGCAGCGGAGATGGTGGA
GTGACGGGTATTTTGAG 
 
 
- 
Oligonucleotides for sequencing/verification of integration or deletion of DNA 
sequences 
pEKEX-fw-2 CGGCGTTTCACTTCTGAGTTCGGC - 
pEKEX-rv-2 GATATGACCATGATTACGCCAAGC - 
rsp CACAGGAAACAGCTATGACCATG - 
univ CGCCAGGGTTTTCCCAGTCACGAC - 
leuA1+ CCGAGACATGACAGCACTGGAACTGGG - 
leuA2+ CGAGGTCGGTTTCCCTTCAGCTTCCC - 
leuA3+ CACAATGACCGTGGCACCGGCGTTGGC - 
leuA4+ CGGTCTGCAGATCCCTCGCTCCATGCAGG - 
leuA_int_c+  CCACTCGATCGATGGATTCCAGTAC - 
leuA_int_c-  TCAATGGTGACCATGCGTGAAGTCG - 
ltbR_int_c+   GAGCAGCAAATCTGGTGGTATAGC - 
ltbR_int_c- AAATGTCACCTCCCGCCCAAAATC - 
ilvE_c+ TTTCAAAACCACCGAGGGAGCGGGC - 
ilvE_c- AGGCCGTCCATGAGGGCTTTGGTG - 
seqilvBNCD1+ GAGCAAATATTGAATGGGTACGCC - 
seqilvBNCD2+ GCTTCTCAACAGCCCACTCCCGCC - 
seqilvBNCD3+ GATTACTGGTCGCCCTGGCCCTGTTC - 
seqilvBNCD4+ TCCAATCGTGGGCGATGCCCGCGAAG - 
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Name DNA Sequence (5´- 3´)a Restriction 
sites 
 
seqilvBNCD5+ 
 
CCTATTCTATGAAGGACGGTACTC 
 
- 
seqilvBNCD6+ CTGCAAAGACCGAAACACACGGCATC - 
seqilvBNCD7+ CGAGTTAAACTCCCACGATTTACAGTG - 
seqilvBNCD8+ ACCAGGACCCAACCGGAACCG - 
seqilvBNCD9+ GCCCTTTGGAATCGGTCCGAAAG - 
seqilvBNCD10+ GTGCACACTTCTTGCCCAGGCCG - 
seqilvBNCD11+ ACCGCGGTTGAGCTCGCCGAG - 
seqilvBNCD12+ CTGCATCGCTTGCGGATGCGGAG - 
Delta-Q down kontr GGTATTCATGTCCGTGCCAGG - 
Delta-Q up kontr GCTCACCGATATTGCGGCG - 
pavtA-delfor CTCCGGTCTGCTTTACGCAGG - 
pavtA-delrev TGTGGGAACGGCCAGCCATGA - 
K_DiolR_fw  GCACGTTATGACCTGCAAACTC - 
K_DiolR_rev TACGGTCTGGCTATCTACATCC - 
gltA upstream ATCGTTAACGATCTGACCCAACAA - 
gltA downstream TCGAGTGGGTTCAGCTGGTCC - 
d_AcT_c+ (cg3022) GCTGAAGCAGCACCTGATCAATCAC - 
d_AcT_c- (cg3022) TGAGAACAGCGCCGCGAGGGAATC - 
pK18_intcheck+   CGGAATGATCTTGACCCTTGTTGGTG  - 
pK18_intcheck-   ATCAAGCAGATCTCTGAGCTGCTGGC - 
a Introduced recognition sites for restriction endonucleases are underlined. 
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2.3 Chemicals and growth media 
2.3.1 Chemicals  
All chemicals used in this work had a minimum quality of “pro analysi” (p.a.). All chemicals 
were purchased from Merck KGaA (Darmstadt, Germany), Fluka (Steinheim, Germany), 
Sigma-Aldrich (Taufkirchen, Germany), Carl Roth GmbH & Co. KG (Karlsruhe, Germany), 
Roche Diagnostics GmbH (Mannheim, Germany), and GE Healthcare (München, Germany). 
Components of complex growth media were purchased from Difco Laboratories (Detroit, 
USA). 
 
2.3.2 Growth media  
C. glutamicum was cultivated in brain heart infusion (BHI) medium (Difco Laboratories, 
Detroit, USA), BHI medium with 9.1% (w/v) sorbitol (BHIS), CGIII complex medium (Menkel 
et al., 1989), or (modified) defined CGXII minimal medium (Keilhauer et al., 1993) with 
4% (w/v) glucose as sole carbon source. Luria-Bertani (LB) medium (Bertani, 1951) was 
used for cultivation of E. coli DH5α. 
 
BHI medium:     37 g/l BHI 
BHIS medium:  37 g/l BHI, 91 g/l sorbitol 
CGIII medium: 10 g/l peptone, 10 g/l yeast extract, 2.5 g/l NaCl,                   
20 g/l glucose; solution was adjusted to pH 7.5 before 
autoclaving; glucose was added after autoclaving   
CGXII medium with 4% (w/v) glucose: 
 20 g/l (NH)4SO4, 5 g/l urea, 1 g/l K2HPO4, 1 g/l KH2PO4, 
0.25 g/l MgS04·7H2O, 10 mg/l CaCl2,                                       
42 g/l 3-morpholinopropanesulfonic acid (MOPS),                                             
trace elements (10 mg/l FeSO4·7H2O, 10 mg/l MnSO4·H2O, 
1 mg/l ZnSO4·7H2O, 0.2 mg/l CuSO4, 0.02 mg/l NiCl2·6H2O), 
0.2 mg/l biotin, 30 mg/l protocatechuic acid, 40 g/l glucose; 
solution was adjusted to pH 7.0 with NaOH before autoclaving; 
trace elements, biotin, protocatechuic acid, and glucose were 
added after autoclaving   
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Modified CGXII medium with 4% (w/v) glucose:  
20 g/l (NH)4SO4, 5 g/l urea, 1.2 g/l K2HPO4, 
0.25 g/l MgSO4·7H2O, 10 mg/l CaCl2,                                                 
trace elements (10 mg/l FeSO4·7H2O, 10 mg/l MnSO4·H2O, 
1 mg/l ZnSO4·7H2O, 0.2 mg/l CuSO4, 0.02 mg/l NiCl2·6H2O), 
0.2 mg/l biotin, 30 mg/l protocatechuic acid; glucose, trace 
elements, biotin, and protocatechuic acid were added after 
autoclaving 
LB medium:   10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl 
 
For preparation of agar plates, 18 g/l agar was added to the medium before autoclaving. 
   
Where appropriate, kanamycin (50 mg/ml stock solution, sterile-filtered) was added as 
selection marker to the medium to a final concentration of 25 µg/ml for C. glutamicum strains 
and 50 µg/ml for E. coli DH5α. To induce the expression of genes carried on pAN6 plasmids, 
0.1 mM isopropyl β-D-thiogalactoside (IPTG) (1 M stock solution, sterile-filtered) was added 
to the medium. For 2-ketoisocaproate (KIC) production in shake flask experiments, pre- and 
main cultures were supplemented with L-isoleucine (and L-leucine) to a final concentration of 
1 mM (100 mM stock solutions, sterile-filtered). For KIC production in bioreactors,                 
0.3 g/l L-isoleucine was added to the medium before autoclaving.  
 
2.4 Cultivation of microorganisms 
The C. glutamicum wild-type strain ATCC 13032 (Abe et al., 1967) and its recombinant 
derivatives were routinely cultivated aerobically at 30°C on agar plates, in test tubes, baffled 
Erlenmeyer flasks, or bioreactors. E. coli DH5α was cultivated aerobically at 37°C on agar 
plates and test tubes. 
 
2.4.1 Maintenance of microorganisms 
C. glutamicum cells were cultivated in test tubes with 5 ml BHI medium for 16 h at 30°C and 
170 rpm. 800 µl of this culture were mixed with 800 µl sterile 28% (v/v) glycerol (in fresh BHI) 
and stored at -70°C. E. coli DH5α cells were cultivated in test tubes with 5 ml LB medium for 
16 h at 37°C and 170 rpm. 600 µl of this culture were mixed with 300 µl sterile 85% (v/v) 
glycerol and stored at -70°C. 
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2.4.2 Cultivation in shake flasks 
For bacterial growth as well as L-leucine and KIC production in shake flask cultivations, 
C. glutamicum strains were grown for 6-8 h in test tubes with 5 ml CGIII medium on a rotary 
shaker at 30°C and 170 rpm (first preculture) and subsequently inoculated into 50 ml CGXII 
medium with 4% (w/v) glucose in 500 ml baffled Erlenmeyer flasks. This second preculture 
was cultivated overnight on a rotary shaker at 30°C and 120 rpm and then used for the 
inoculation of the main culture to an OD600 of 0.5 (if not stated otherwise). Medium and 
growth conditions for the main culture were the same as for the second preculture. During 
the cultivation, samples were taken for measuring OD600 and then centrifuged at 16,000 x g 
for 5 min. The resulting cell-free supernatants were employed for the quantification of amino 
acids, glucose, and organic acids. 
 
2.4.3 Cultivation in bioreactors 
Batch and fed-batch cultivations of C. glutamicum strains for L-leucine and KIC production 
were performed in 1.4 l bioreactors of the Multifors multifermenter system from Infors GmbH 
(Einsbach, Germany). Each reactor was equipped with a suitable polarimetric oxygen 
electrode (Mettler-Toledo GmbH, Gießen, Germany) for measurement of the oxygen partial 
pressure (pO2), a suitable pH electrode (Mettler-Toledo), and an Exit Gas Analyzer (Infors) 
for exhaust gas analysis of O2 and CO2. Process parameters were controlled and monitored 
by IRIS software (Infors, Einsbach, Germany). Reactors were filled with modified CGXII 
minimal medium with 4% (w/v) glucose. Modified CGXII minimal medium was used because 
MOPS was not needed for buffering due to the automatic pH control (see below). The 
reduced phosphate amounts resulted in limitation of biomass in the feed phase. Cells were 
precultured in CGIII medium and CGXII minimal medium with 4% (w/v) glucose as it was 
described for the shake flask cultivations (section 2.4.2). The main culture in the bioreactor 
was inoculated with cells in the mid exponential phase (OD600 = 10-15) to an OD600 of 1 for 
starting the batch phase. The culture was aerated with a constant rate of 0.9 vvm (volume 
per volume per minute) with compressed air and kept at 30°C. The pH was kept constant at 
value 6.5, 7.2, or 8.0 by automatic addition of 3 M NaOH and 3 M HCl. A 
25% (v/v) Antifoam 204/water suspension (Sigma-Aldrich, Steinheim, Germany) was added 
to the bioreactor to prevent foam formation when necessary. The stirrer speed was set to 
500 rpm and was automatically increased up to 800 rpm to keep the dissolved oxygen 
saturation, represented by the pO2 value, above 30%. When necessary, compressed air was 
mixed with pure oxygen to provide sufficient oxygen supply. The end of the batch phase was 
indicated by a raise of pO2 to >80%, indicating a depletion of glucose. The feed phase started 
with the addition of feed solution (50% (w/v) glucose with or without 4% (w/v) ammonium 
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sulfate). Stirrer speed was manually adjusted to keep pO2 >30% in the fed-batch mode. An 
automatic feeding program was conducted as follows: as soon as pO2 raised above 80% 
again, feed solution was added to the bioreactor for 4 min (corresponding to approximately 
15 ml feed solution). Samples were taken during the cultivation for measuring OD600. Cell-
free supernatants were obtained by centrifugation at 16,000 x g for 5 min and used for 
quantification of amino acids, glucose, and organic acids. 
 
2.4.4 Determination of bacterial growth 
Bacterial growth was followed by measuring the optical density at 600 nm (OD600) with an 
Ultrospec 3000 UV/visible spectrophotometer from Amersham Pharmacia Biotech (Freiburg, 
Germany). A water sample served as blank. To maintain linearity between absorbance and 
cell concentration, samples were diluted with water to gain absorbance values between 0.1 
and 0.5. 
 
2.5 Molecular biological work 
Routine methods of molecular cloning like PCR, gel electrophoresis, DNA restriction, and 
ligation were carried out according to standard protocols (Sambrook and Russell, 2001) and 
manufacturer´s instructions. 
 
2.5.1 Preparation of plasmid DNA from E. coli cells 
Plasmid DNA from E. coli DH5α cells was isolated using the GeneJET Plasmid Miniprep Kit 
from Thermo Scientific (Schwerte, Germany) according to the manufacturer’s instructions. 
Cells used for plasmid preparation were grown in 5 ml LB medium in test tubes for 16 h at 
37°C and 170 rpm on a rotary shaker. 
 
2.5.2 Preparation of genomic DNA from C. glutamicum cells  
Genomic DNA from C. glutamicum cells was isolated using the DNAeasy Blood & Tissue Kit 
from Qiagen (Hilden, Germany) according to the manufacturer’s instructions for application 
with gram-positive bacteria. Cells for this preparation were grown for 16 h in a test tube with 
5 ml BHI medium at 30°C and 170 rpm on a rotary shaker. 
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2.5.3 Polymerase chain reaction 
Polymerase chain reaction (PCR) (Mullis et al., 1986) was used for amplification of DNA 
fragments, for verification of cloning steps in E. coli DH5α cells, and for detection of desired 
integration or deletion mutants of C. glutamicum (colony-PCR) using a T3000 thermocycler 
from Biometra (Göttingen, Germany). For amplification of DNA fragments, the DNA 
polymerase Phusion Hot Start II from Thermo Scientific (Schwerte, Germany) was employed. 
DreamTaq DNA polymerase (Thermo Scientific) was used for verification of cloning steps 
and for colony-PCR. For the latter, a single colony was directly added to the PCR reaction 
mix. PCR setup (i.e. choice of reaction components, annealing temperature, elongation time) 
was done according to the manufacturer’s instructions. 
 
2.5.4 Purification of DNA fragments  
For purification of DNA fragments after e.g. PCR or restriction digest, the MinElute PCR 
Purication Kit from Qiagen (Hilden, Germany) was used according to the manufacturer’s 
instructions. 
 
2.5.5 DNA agarose gel electrophoresis 
For separation and sizing of DNA fragments, gel electrophoresis with 1% (w/v) agarose gels 
in TAE buffer (40 mM tris(hydroxymethyl)aminomethane (Tris), 20 mM acetic acid, 
1 mM ethylenediaminetetraacetic acid (EDTA)) was used. DNA samples were mixed with 
6 x DNA Loading Dye from Thermo Scientific (Schwerte, Germany). Electrophoresis was 
carried out in Mini-Sub Cell GT electrophoresis chambers from Bio-Rad Laboratories GmbH 
(München, Germany) connected to a Power Pac 2000 station (Bio-Rad) at 90 V for 30-
45 min. Afterwards, agarose gels were stained in an ethidium bromide solution (0.5 μg/ml). 
DNA bands were detected under UV light and documented using Quantum gel 
documentation system from Peqlab Biotechnologie GmbH (Erlangen, Germany). GeneRuler 
1 kb DNA Ladder (Thermo Scientific) was employed for sizing of DNA fragments. 
 
2.5.6 Extraction of DNA fragments from agarose gels 
The MinElute Gel Extraction Kit from Qiagen (Hilden, Germany) was used for isolation of 
DNA fragments from agarose gels according to the manufacturer’s instructions. 
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2.5.7 Determination of nucleic acid concentration 
Concentration of DNA and RNA samples was determined by measuring the absorbance at                
260 nm (A260nm) using a NanoDrop ND-1000 spectrophotometer from Peqlab Biotechnologie 
GmbH (Erlangen, Germany). Purity of nucleic acid preparations was displayed by the ratio of 
the absorbance value at 260 nm (A260nm) and the absorbance value at 280 nm (A280nm). This 
ratio should be 1.8-2.0 for pure DNA or RNA. A260nm = 1 is equal to 50 ng/µl double stranded 
DNA or 40 ng/µl RNA, respectively. 
 
2.5.8 DNA sequencing  
DNA sequencing was provided by Eurofins MWG Operon (Ebersfeld, Germany) and used for 
verification of constructed plasmids as well as chromosomal deletions or integrations in 
engineered strains. Samples were prepared according to the provider’s instructions and 
sequencing results were analyzed using the software CloneManager 9 Professional Edition 
(Scientific & Educational Software, Cary, USA). 
 
2.5.9 Restriction digest and modification of DNA 
FastDigest restriction endonucleases from Thermo Scientific (Schwerte, Germany) were 
used for restriction digest of DNA templates according to the manufacturer’s instructions. 
Reactions were carried out for 0.5-2 h at 37°C. To prevent religation of plasmid DNA, 
1 μl Shrimp Alkaline Phosphatase (Thermo Scientific) was added to the respective samples. 
 
2.5.10 Ligation of DNA  
For ligation of digested DNA fragments, the Rapid DNA Ligation Kit from Thermo Scientific 
(Schwerte, Germany) was used according to the manufacturer’s instructions. Ligation 
reaction was carried out for 30-60 min at RT. 
 
2.5.11 Preparation and transformation of competent C. glutamicum cells 
For preparation of competent cells, C. glutamicum strains were inoculated into 5 ml BHIS 
medium in a test tube and grown overnight on a rotary shaker at 30°C and 170 rpm. 100 ml 
BHIS medium in a 1000 ml baffled Erlenmeyer flask were inoculated with this preculture and 
grown on a rotary shaker at 30°C and 120 rpm to an OD600 of approximately 1.75. Cells were 
harvested by centrifugation (25 min; 4,000 x g; 4°C) and washed three times with cold sterile 
10% (v/v) glycerol via centrifugation steps (15 min; 4,000 x g; 4°C). Finally, cells were 
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resuspended in 1 ml sterile 10% (v/v) glycerol. Cells were frozen in liquid nitrogen as 150 μl 
aliquots and stored at -70°C. 
Transformation of competent C. glutamicum cells was done by electroporation and 
subsequent heat-shock (van der Rest et al., 1999). 150 μl competent cells were mixed with 
0.2-1 μg of DNA in a precooled electroporation cuvette (Typ Gene Pulser Cuvette, 0.1 cm, 
Bio-Rad Laboratories GmbH, München, Germany) and coated with 800 μl cold sterile 
10% (v/v) glycerol. Electroporation (settings: 2.5 kV, 200 Ω, 25 μF) was carried out with the 
Gene Pulser Xcell device from Bio-Rad Laboratories GmbH (München, Germany). 
Afterwards, cells were incubated for 6 min in 4 ml BHIS medium at 46°C (heat shock), 
regenerated for at least 1 h at 30°C and 170 rpm on a rotary shaker, and eventually plated 
on BHIS agar with the respective selection marker (kanamycin). 
 
2.5.12 Preparation and transformation of competent E. coli cells 
For preparation of competent cells (Hanahan, 1983), E. coli DH5α cells were inoculated into 
5 ml LB medium in a test tube and grown overnight on a rotary shaker at 37°C and 170 rpm. 
100 μl of this preculture were used for inoculation of 70 ml LB medium in a 500 ml baffled 
Erlenmeyer flask. Cells were grown to an OD600 of approximately 0.5 at 37°C and 120 rpm, 
chilled in ice-cold water, and then harvested by centrifugation (10 min; 4,000 x g; 4°C). The 
cell pellet was resuspended in 15 ml sterile 70 mM CaCl2/20 mM MgSO4 solution, incubated 
for 30 min on ice, and then harvested by centrifugation (10 min; 4,000 x g; 4°C). After 
resuspension in 5 ml sterile 70 mM CaCl2/20 mM MgSO4 solution, cells were incubated on 
ice for 30 min. Finally, 1.25 ml sterile 85% (v/v) glycerol was added. Competent cells were 
frozen in liquid nitrogen as 200 μl aliquots and stored at -70°C. 
Competent E. coli DH5α cells were transformed with 10-100 ng of plasmid DNA via heat-
shock: Cells were incubated for 90 sec at 42°C and then regenerated in 800 μl LB medium 
for 1 h at 37°C and 170 rpm on a rotary shaker. Eventually, cells were plated on LB agar with 
the respective selection marker (kanamycin). 
 
2.5.13 Integration and deletion of genes using the pK19mobsacB system 
Marker-free integrations or in-frame deletions of DNA sequences in C. glutamicum strains 
were done via two-step homologous recombination based on vector pK19mobsacB (Schäfer 
et al., 1994) and a method described by Niebisch and Bott (2001): DNA sequences to be 
integrated or deleted were cloned together with their >500 bp up- and downstream regions 
into vector pK19mobsacB. After transformation of the respective C. glutamicum strain, clones 
with integrated vector were selected using BHIS agar plates with 25 µg/ml kanamycin. Since 
pK19mobsacB is a non-replicative plasmid, appearance of kanamycin-resistant cells 
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depends on integration of the plasmid into the genome via homologous recombination. For 
excision of the vector, clones were incubated in 5 ml BHI medium without kanamycin in test 
tubes at 30°C and 170 rpm on a rotary shaker for 3-5 h and plated on BHI agar plates with 
10% (w/v) sucrose. The vector pK19mobsacB carries the gene sacB. This gene codes for 
the enzyme levansucrase that catalyzes sucrose hydrolysis and synthesis of levan, which is 
lethal to C. glutamicum (Jäger et al., 1992). Using plates with sucrose, only clones which had 
had excised the vector were selected. Finally, clones which showed both sucrose-resistance 
and kanamycin-sensitivity were checked via colony-PCR and DNA sequencing for proper 
gene integration or deletion.  
 
2.5.14 Plasmid construction 
For the construction of pAN6-leuA_wt and pAN6-leuA_B018, gene leuA encoding for                   
2-isopropylmalate synthase was amplified using the oligonucleotide pair 
NdeI_leuA_B018_Fw/EcoRI_leuA_B018_Rev from genomic DNA of C. glutamicum wild type 
and B018, respectively. The resulting DNA fragments were each digested with the restriction 
enzymes NdeI and EcoRI and separately ligated into the plasmid pAN6 cut with the same 
enzymes. 
Overlap-extension PCR was applied for the construction of plasmid pAN6-leuA_mod: Two 
DNA fragments (276 bp and 1614 bp, respectively) were amplified from genomic DNA of 
C. glutamicum wild type via the oligonucleotide pairs NdeI_leuA_B018_Fw/ 
leuA_ASAustausch_Rev and leuA_ASAustausch_Fw/EcoRI_leuA_B018_Rev, together 
covering gene leuA. The two fragments were fused via a 24 bp overlap-region in a PCR 
reaction to yield a leuA gene with mutations leading to amino acid exchanges G530D, 
G532D, and A535T. This gene was amplified using the oligonucleotides 
NdeI_leuA_B018_Fw and EcoRI_leuA_B018_Rev, digested with the restriction 
endonucleases NdeI/EcoRI and finally ligated into the equally digested plasmid pAN6. 
To obtain the vector pK19mobsacB-leuA_B018_BS, a 1378 bp PCR fragment was 
generated from genomic DNA of B018 using the oligonucleotides 
Sbf1_leuA_B018_intern_Fw and XbaI_leuA_int_down_Rev. It covered the partial sequence 
of leuA from B018 coding for the amino acid exchanges R529H and G532D in comparison to 
the wild-type sequence along with its upstream and downstream regions (approximately 
560 bp and 810 bp, respectively). The fragment was cut with the restriction endonucleases 
SbfI and XbaI and ligated into the vector pk19mobsacB that had been digested with the 
same enzymes.  
The vector pK19mobsacB-ΔleuA was constructed via overlap-extension PCR: The region 
upstream (approximately 490 bp) of the 180 bp upstream region of leuA as well as the 
downstream region (approximately 550 bp) of leuA were amplified via the oligonucleotide 
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pairs SbfI_leuA_int_up_Fw/NdeI-MluI-SpeI-leuA_int_Rev and NdeI-MluI-SpeI-leuA_int_Fw/ 
XbaI_ leuA_int_down_Rev, respectively, from genomic DNA of C. glutamicum wild type. The 
amplified DNA fragments were fused in an overlap-extension PCR resulting in a 1060 bp 
PCR product that was amplified with the oligonucleotides SbfI_leuA_int_up_Fw and 
XbaI_leuA_int_down_Rev. This fragment was digested with the restriction enzymes SbfI/ 
XbaI and ligated into the equally digested vector pK19mobsacB. 
The plasmid pK19mobsacB-Ptuf-leuA_B018 was constructed as follows: The gene leuA 
from B018 (leuA_B018) was amplified via the oligonucleotides leuA_B018_amp_Fw and 
leuA_B018_amp_Rev; the sequence of the tuf promoter (Ptuf, 178 bp upstream of the coding 
sequence of the tuf gene) (Becker et al., 2005) was amplified using the oligonucleotide pair 
NdeI_Peftu_Fw/MluI_Peftu_Rev. First, the leuA_B018 PCR fragment was cut with the 
restriction enzymes MluI and SpeI and ligated into pK19mobsacB-ΔleuA. In a second step, to 
finally obtain plasmid pK19mobsacB-Ptuf-leuA_B018, the resulting plasmid was cut with the 
endonucleases NdeI and MluI and ligated with the Ptuf DNA fragment digested with the same 
enzymes.  
For the construction of vector pK19mobsacB-ΔltbR::Ptuf-leuA_B018, the leuA gene from                           
B018 under control of the tuf promoter and, to cover the transcription terminator sequence of 
this gene, the region approximately 70 bp upstream of leuA were amplified by use of 
oligonucleotides AvrII_Peftu_Fw and AvrII_leuA_Rev. The program Mfold (Zuker, 2003) was 
used to predict the transcription terminator sequence of leuA 
(http://mfold.rna.albany.edu/?q=mfold). The resulting PCR fragment was digested with AvrII 
and ligated into pK19mobsacB-ΔltbR which had been digested in the same way.  
The plasmid pK18mobsacB-Ptuf-leuA_B018 was constructed similarly by amplifying the 
coding sequence for tuf promoter and leuA from B018 along with its 54 bp downstream 
region to cover the transcription terminator sequence from pK19mobsacB-Ptuf-leuA_B018 via 
the oligonucleotides XhoI-Peftu_Fw and EcoRI-leuA_Rev. The DNA fragment was digested 
with the restriction enzymes XhoI and EcoRI and ligated with the 7.2 kb plasmid backbone 
originating from plasmid pK18mobsacB-lysOP7 digested with the restriction enzymes XhoI 
and EcoRI.                                                                                                                 
Overlap-extension PCR was applied for the construction of vector pK19mobsacB-ilvN_fbr: 
The upstream region (approximately 620 bp) and the downstream region (approximately 
660 bp) of the partial sequence of ilvN coding for the amino acids G20, I21, and I22 was 
amplified via the oligonucleotide pairs SbfI_ilvN_up_Fw/SOE_ilvN_Rev and 
SOE_ilvN_Fw/XbaI_ilvN_down_Rev, respectively, from genomic DNA of C. glutamicum wild 
type. The amplified DNA fragments were fused in a PCR reaction via a 23 bp overlap-region 
that introduced mutations into ilvN leading to amino acid exchanges G20D, I21D, and I22F. 
This 1279 bp fusion product was amplified using oligonucleotides SbfI_ilvN_up_Fw and 
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XbaI_ilvN_down_Rev, digested with the restriction endonucleases SbfI and XbaI, and finally 
ligated into the equally digested vector pK19mobsacB. 
The vector pK19mobsacB-Δcg3022 was constructed via overlap-extension PCR: The 
regions upstream (approximately 570 bp) and downstream (approximately 510 bp) of cg3022 
were amplified via the oligonucleotide pairs SbfI_AcT_Fw/SOE_AcT_Rev and 
SOE_AcT_Fw/EcoRI_AcT_Rev, respectively, from genomic DNA of C. glutamicum wild type. 
The amplified DNA fragments were fused and the resulting 1172 bp fragment amplified via 
the oligonucleotides SbfI_AcT_Fw and EcoRI_AcT_Rev. This fragment was digested with 
the restriction enzymes SbfI/EcoRI and ligated into the equally digested vector 
pK19mobsacB. 
 
2.5.15 Preparation of RNA 
For preparation of total RNA of C. glutamicum strains, cells were cultivated in 50 ml CGXII 
minimal medium with 4% (w/v) glucose to an OD600 of 5. An aliquot of 25 ml was centrifuged 
(3 min; 4,000 x g; 4°C) with 25 g ice. The cell pellet was frozen in liquid nitrogen and stored 
at -70°C. Mechanical cell disruption was performed via Silamat S5 from Ivoclar Vivadent 
GmbH (Ellwangen, Germany) using 400 mg silica beads (diameter 0.1 mm) for 4 x 20 sec. 
The isolation and purification of RNA was done using the RNeasy Mini Kit from Qiagen 
(Hilden, Germany) according to the manufacturer’s instructions. Integrity of RNA was 
checked via RNA agarose electrophoresis before further use and isolated RNA (100-150 μg) 
was stored at -20°C. 
 
2.5.16 RNA agarose gel electrophoresis 
For separation of RNA fragments, denaturing gel electrophoresis with 1.5% (w/v) agarose 
gels in MOPS buffer (50 mM MOPS, 1 mM EDTA, 1.5% (v/v) formaldehyde) was used. 
Before electrophoresis, RNA samples were mixed with the fourfold amount of RNA loading 
dye (50 mM MOPS, 50% (v/v), formamide, 7% (v/v) formaldehyde, 15% (v/v) glycerol, 
0.1% (w/v) bromophenol blue, 0.5% (w/v) ethidium bromide), denatured for 2 min at 65°C, 
and then chilled on ice for 5 min. Electrophoresis was carried out in Mini-Sub Cell GT 
electrophoresis chambers from Bio-Rad Laboratories GmbH (München, Germany) 
connected to a Power Pac 2000 station (Bio-Rad) at 75 V for 45 min. RNA bands were 
detected under UV light and documented using Quantum gel documentation system from 
Peqlab Biotechnologie GmbH (Erlangen, Germany). 
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2.5.17 Synthesis and labeling of cDNA  
Isolated total RNA samples were converted into fluorescently labeled cDNA (Polen et al., 
2007). 30 μg of RNA were mixed with 500 ng Random Primers from Invitrogen (Karlsruhe, 
Germany), filled up with RNase-free water to 15 μl, incubated for 10 min at 65°C, and then 
chilled on ice for 2 min. Samples were either mixed with 3 μl of 1 mM green-fluorescing 
nucleotide analoge FluoroLink Cy3-dUTP or red-fluorescing FluoroLink Cy5-dUTP from 
GE Healthcare (München, Germany). Then, 11.6 μl of a reverse transcriptase mastermix 
were added. 
Reverse transcriptase mastermix:  6 μl 0.1 M dithiotreitol  
     12 μl 5 x 1st Strand Buffer (Invitrogen) 
1.2 μl dNTP-Mix (Invitrogen):  
25 mM dATP, 25 mM dCTP,  
25 mM dGTP, 10 mM dTTP 
4 μl Superscript II Reverse Transcriptase (Invitrogen) 
Samples were incubated for 10 min at RT and then for 110 min at 42°C. Reaction was 
stopped by adding 10 μl 0.1 M NaOH at 70°C to hydrolyze RNA. 10 μl 0.1 M HCl were used 
for neutralization. 
For sample purification, Microcon YM-30 columns from Millipore (Schwalbach, Germany) 
were employed. 50 μl of sample were mixed with 450 μl bidist. H2O in the column and the 
volume was reduced to 20 μl by centrifugation (10 min; 16,000 x g; RT). The column was 
refilled to 500 μl and the volume was reduced to 20 μl again. Cy3- and Cy5-marked samples 
to be compared in DNA microarray analysis were pooled and refilled to 500 μl with bidist. 
H2O in a Microcon column. Finally, the volume was reduced to < 44 μl by centrifugation and 
samples were directly used for hybridization on DNA microarrays.  
2.5.18 DNA microarray analysis     
Custom-made 4 x 44K 60mer DNA microarrays for genome-wide gene expression analysis 
were obtained from Agilent Technologies (Waldbronn, Germany) and were designed using 
Agilent’s eArray platform (https://earray.chem.agilent.com/earray). The array design included 
oligonucleotides for annotated protein-coding genes and structural RNA genes of the 
genomes from C. glutamicum and three other bacterial species (E. coli,                    
Gluconobacter oxydans, and Bacillus subtilis). For C. glutamicum, the genome annotation by 
Kalinowski et al. (2003) listing 3057 protein-coding genes and 80 structural RNA genes 
(tRNAs and rRNAs) was used (accession number NC_006958). The custom array design 
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comprised each of these genes, represented by one to three oligonucleotides, and Agilent’s 
control spots. 
For comparison of global gene expression of selected C. glutamicum strains, pooled 
labeled cDNA was hybridized at 65°C for 17 h on the 4 x 44K arrays using Agilent’s gene 
expression hybridization kit, Agilent’s hybridization chamber, and Agilent’s hybridization oven 
according to the manufacturer’s instructions. After hybridization, the arrays were washed 
using Agilent’s wash buffer kit according to the manufacturer’s instructions. Subsequently the 
fluorescence of DNA microarrays was determined at 532 nm (Cy3-dUTP) and 635 nm              
(Cy5-dUTP) at 5 µm resolution with a GenePix 4000B laser scanner and GenePix Pro 6.0 
software from Molecular Devices (Sunnyvale, USA). Raw data files of fluorescence images 
were saved in TIFF format (GenePix Pro 6.0) followed by quantitative image analysis using 
GenePix image analysis software and Agilent’s gene array list (GAL) file. Results were saved 
as GPR-file (GenePix Pro 6.0) and processed using the BioConductor R-packages limma 
and marray (http://www.bioconductor.org) to achieve background correction of spot 
intensities, ratio calculation/normalization, and diagnostic-plot generation for array quality 
control. For analysis, processed and loess-normalized data along with detailed information 
about the experiments according to the MIAME standard (Brazma, 2009) were saved in the 
in-house DNA microarray database (Polen and Wendisch, 2004). Analysis of differentially 
expressed genes was carried out using GenePix Pro 6.0 software (Molecular Devices, 
Sunnyvale, USA) by filtering processed Cy5/Cy3 ratios reflecting the relative mRNA level 
using the following criteria: (i) Flags ≥ 0; (ii) signal/noise of Cy5 (F635Median/B635Median) 
or Cy3 (F532Median/B532Median) ≥ 3. For calculation of p-values, paired Student’s t-test 
was used comparing the relative RNA levels of a gene in the replicates to the relative RNA 
levels of all other genes in the replicates. 
 
2.6 Quantification of metabolites 
2.6.1 Quantification of amino acids 
Reversed phase high-pressure liquid chromatography (RP-HPLC) with automatic                          
o-phthaldialdehyde precolumn derivatization (Jones & Gilligan 1983) was used for amino 
acid quantification in culture supernatants using a 1290 Infinity System from Agilent 
Technologies (Waldbronn, Germany) equipped with a ZORBAX Eclipse AAA column 
(4.6 x 75 mm 3.5-Micron), a ZORBAX Analytical Guard column (4.6 x 12.5 mm 5-Micron), 
and an Agilent 1260 fluorescence detector. A gradient of 10 mM Na2HPO4/10 mM Na2B4O7 
(pH 8.2) buffer with increasing concentrations of methanol was used as eluent. HPLC-
samples were separated at 40°C at a flow rate of 2 ml min-1 for 11.5 min. The detection of the 
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fluorescent isoindole derivatives was performed using an excitation wavelength of 230 nm 
and an emission wavelength of 450 nm. The concentration of the amino acids was 
determined by comparison with defined external standards of the respective amino acids. 
The program Chemstation (Agilent) was used for data evaluation. HPLC-samples were 
diluted 1:100-1:1000. 
 
2.6.2 Quantification of organic acids and glucose 
The detection and quantification of organic acids and glucose in culture supernatants was 
performed using an Agilent 1100 liquid chromatography system (Agilent Technologies, 
Waldbronn, Germany) equipped with an organic acid column (300 x 8 mm polystyrol-
divinylbenzol resin) from CS Chromatographie Service GmbH (Langerwehe, Germany) and a 
suitable guard cartridge (40 x 8 mm). Organic acids and glucose were separated by isocratic 
elution at 40°C with 100 mM sulfuric acid for 38 min at a flow rate of 0.4 ml min-1. Samples 
were diluted 1:4. Separation of keto acids (dilution 1:10) in particular was performed using 
isocratic elution with 10 mM sulfuric acid for 15 min at 70°C and a flow rate of 1.1 ml min-1. 
Organic acids were detected via an Agilent 1100 diode array detector at 215 nm; glucose 
was detected via an Agilent 1100 refractive index detector. Quantification was performed 
with the program Chemstation (Agilent) using external standards of glucose and the 
respective organic acids. 
 
2.6.3 Calculation of glucose uptake rate 
Glucose uptake rates were determined as described by Frunzke et al. (2008): 
 
�
SM� × 𝜇 �� mmol × l−1 × OD600−1g CDW × l−1 × OD600−1� × h−1� = � mmol g CDW × h� 
 
S represents the slope of a plot of the substrate concentration in the medium versus the 
OD600 (mmol l-1 OD600-1), M is the correlation between cell dry weight (CDW) and 
OD600 (g CDW l-1 OD600-1) and μ is the growth rate (h-1).  
Cell dry weight was calculated according to Kabus et al. (2007): An OD600 of 1 corresponds 
to 0.25 g CDW l-1. 
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2.7 Protein biochemical methods 
2.7.1 Preparation of crude cell extract 
Crude cell extracts were prepared for the determination of 2-isopropylmalate synthase 
(IPMS) and 3-isopropylmalate dehydratase (IPMD) activity. Cells were grown in CGXII 
minimal medium with 4% (w/v) glucose to an OD600 of 5, harvested by centrifugation (10 min; 
4,000 x g; 4°C), and then resuspended in 1 ml 50 mM Tris-HCl buffer (pH 7.5) with 200 mM 
potassium glutamate for the IPMS assay or in 200 mM potassium phosphate buffer (pH 7.0) 
for the IPMD assay. Cell suspensions were disrupted by sonication for 5 min on ice using a 
Branson Sonifier W-250 (Branson Sonic Power, Danbury, USA) and cell debris was removed 
by centrifugation (5 min; 16,000 x g; 4°C). The resulting crude extracts with protein 
concentrations of 2-5 mg ml-1 were finally used for the respective enzyme assays. 
 
2.7.2 Determination of protein concentration 
Protein concentrations of crude extracts were determined by a modified Lowry assay as 
described by Bensadoun and Weinstein (1976): 1 ml crude extract (diluted 1:100-1:200) was 
mixed with 50 μl 0.3% (w/v) sodium deoxycholate and incubated for 15 min at RT. After 
mixing with 200 μl 36% (w/v) trichloroacetate, the solution was centrifuged (10 min; 
16,000 x g; RT) and the supernatant was discarded. 1 ml Lowry reagent (0.01% (w/v) 
CuSO4·5H2O, 0.02% (w/v) sodium potassium tartrate, 0.02% (w/v) Na2CO3 in 0.1 M NaOH) 
was added to the protein pellet, mixed, and incubated for 30 min at RT in the dark after 
adding 100 μl diluted Folin's reagent (1:2 in bidist. H2O). Finally, absorbance was measured 
at 660 nm with an Ultrospec 3000 UV/visible spectrophotometer from Amersham Pharmacia 
Biotech (Freiburg, Germany). A mix of Lowry solution and Folin's reagent was used as blank. 
The protein concentrations were determined by comparison with a defined standard of               
0-50 μg bovine serum albumin which was treated like the samples. 
 
2.7.3 Enzyme assay for 2-isopropylmalate synthase  
2-Isopropylmalate synthase (IPMS) activity, KM values for 2-ketoisovalerate (KIV) and acetyl-
CoA, as well as Ki value for L-leucine were determined at 30°C using a continuous 
spectrophotometric assay measuring coenzyme A formation with Ellmann’s reagent 
(Kohlhaw, 1988a). The assay solution contained 500 μl 50 mM Tris-HCl buffer (pH 7.5) with 
400 mM potassium glutamate, 100 μl 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) solution 
(1 mM in 50 mM Tris-HCl, pH 7.5), 50 μl acetyl-CoA solution (3 mM in 50 mM Tris-HCl, 
pH 7.5), 295 μl bidist. H2O, and 50 μl crude extract (diluted 1:1-1:5). The reaction was started 
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by adding 5 μl KIV solution (40 mM in 50 mM Tris-HCl, pH 7.5). Liberated CoA was 
measured at 412 nm with an Ultrospec 3000 UV/visible spectrophotometer from Amersham 
Pharmacia Biotech (Freiburg, Germany). Enzyme activities were calculated with SWIFT II 
software from Biochrom Ltd. (Cambridge, UK) using an extinction coefficient of                  
13,600 M-1 cm-1 for the 5-thio-2-nitrobenzoate dianion.                                       
 
2.7.4 Enzyme assay for 3-isopropylmalate dehydratase 
3-Isopropylmalate dehydratase (IPMD) activity was determined at 30°C using a continuous 
spectrophotometric assay measuring formation of the reaction intermediate                                  
2-isopropylmaleate (Kohlhaw, 1988b). 50 μl crude extract (diluted 1:1-1:100) was mixed with 
400 μl 200 mM potassium phosphate buffer (pH 7.0) and 510 μl bidist. H2O. The reaction 
was started by adding 40 μl 3-isopropylmalate solution (40 mM in bidist. H2O). The increase 
of absorbance at 235 nm was measured with an Ultrospec 3000 UV/visible 
spectrophotometer from Amersham Pharmacia Biotech (Freiburg, Germany). Enzyme 
activities were calculated with SWIFT II software from Biochrom Ltd. (Cambridge, UK) using 
an extinction coefficient of 4,530 M-1 cm-1 for 2-isopropylmaleate.                                         
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3 Results 
3.1 The role of leuA-encoded 2-isopropylmalate synthase for increased           
L-leucine production  
3.1.1 Analysis of the L-leucine producer B018 
As a starting-point for this work, a weak L-leucine accumulating C. glutamicum strain named 
B018 was obtained from Amino GmbH (Frellstedt, Germany). This strain had been generated 
by the classical approach of random mutagenesis and subsequent screening for production. 
In shake flask cultivations with CGXII minimal medium and 4% (w/v) glucose, B018 
accumulated 7.8 ± 2.0 mM L-leucine. Strain B018 had no auxotrophies and grew in the 
defined mimimal medium CGXII, but showed a significantly reduced growth rate (µ) of 
0.23 ± 0.01 h-1 in comparison to the wild-type ATCC 13032 (µ = 0.44 ± 0.01 h-1). As a first 
step to elucidate the reason for the ability of B018 to produce L-leucine, genes ilvBNCD, that 
code for enzymes catalyzing the formation of the L-leucine precursor 2-ketoisovalerate (KIV), 
and leuA encoding 2-isopropylmalate synthase (IPMS), were sequenced. The latter enzyme 
catalyzes the first step specific for L-leucine biosynthesis, the conversion of KIV and              
acetyl-CoA to 2-isopropylmalate and CoA, and is feedback-inhibited by L-leucine (Pátek et 
al., 1994). There were no mutations found in ilvBNCD, but the sequence of leuA from B018 
showed differences with respect to the sequence of the wild-type ATCC 13032 (Kalinowski et 
al., 2003): Two nucleotide exchanges (G1586A, G1595A) were identified, leading to amino 
acid exchanges R529H and G532D (Table 4). Subsequently, leuA from B018 was 
characterized to prove whether this allele is responsible for L-leucine accumulation. 
 
3.1.2 Characterization of the leuA-encoded IPMS from wild-type ATCC 13032 and B018  
The leuA genes from C. glutamicum wild type and strain B018 (leuA_wt and leuA_B018, 
respectively) were cloned into the expression vector pAN6, resulting in plasmids pAN6-
leuA_wt and pAN6-leuA_B018. These plasmids were transferred into C. glutamicum wild 
type and the IPMS activity of crude extracts was determined. Both strains showed 
comparable specific IPMS activities of 0.59-0.63 μmol min-1 mgprotein-1, which were 10- to 20-
fold higher than the activities of the wild type and strain B018 (Table 5). Remarkably, the 
affinities of the mutated IPMS towards its substrates KIV and acetyl-CoA were comparable to 
those of the wild-type enzyme, but the feedback-inhibition by L-leucine was abolished 
(Table 6). The activity of wild-type IPMS was 50% inhibited by 0.4 mM L-leucine, whereas 
IPMS activity from strain B018 was not inhibited even by 40 mM L-leucine.  
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Next, L-leucine accumulation was assayed: The strain carrying pAN6-leuA_wt 
accumulated 0.8 ± 0.1 mM L-leucine, whereas the strain with pAN6-leuA_B018 accumulated 
40.7 ± 0.4 mM L-leucine in the culture supernatant. These data disclose the significance of 
feedback-resistant IPMS for L-leucine overproduction. In order to test the influence of 
feedback-resistant IPMS in single copy, the leuA mutations R529H and G532D were 
introduced into the wild-type genome. The resulting strain MV-Leu7 
accumulated 6.9 ± 0.5 mM L-leucine (Figure 4), indicating that also increased expression of 
leuA_B018 is necessary to obtain high L-leucine concentrations.  
 
3.1.3 Construction of further feedback-resistant IPMS  
IPMS of C. glutamicum shares 61% amino acid sequence identity with the homologous 
enzyme of Mycobacterium tuberculosis and the crystal structure of the mycobacterial protein 
revealed that the amino acid residues G531, G533, and A536 form an L-leucine-binding 
pocket (Koon et al., 2004). The corresponding residues in IPMS from C. glutamicum are 
G530, G532, and A535. Since the amino acid exchanges found in IPMS of B018 (R529H and 
G532D) are located in this region, it was assumed that the feedback-resistance of this variant 
is attributed to an impairment of its L-leucine-binding pocket. Another modified IPMS variant 
(IPMS_mod) was constructed carrying the amino acid exchanges G530D, G532D, and 
A535T to completely disturb the binding pocket (Table 4). The respective leuA_mod gene 
was cloned into the expression vector pAN6, resulting in pAN6-leuA_mod that was 
transferred into C. glutamicum wild type. IPMS_mod indeed showed no feedback-inhibition 
as IPMS_B018 (Table 6), but exhibited a decreased specific activity and lower L-leucine 
accumulation in comparison to IPMS from B018 when performing plasmid-based 
overexpression in shake flask cultivations (Table 5). Therefore, IPMS_B018 was used for 
further studies. 
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Table 4. Differences in DNA and amino acid sequences of wild-type IPMS (IPMS_wt), 
IPMS from strain B018 (IPMS_B018), and constructed modified IPMS (IPMS_mod)a,b. 
Amino acid 
position 
529 530 531 532 533 534 535 
        
IPMS_wt:        
DNA codon CGC GGC AAC GGC CCA CTG GCC 
Amino acid R G N G P L A 
        
IPMS_B018:        
DNA codon CAC GGC AAC GAC CCA CTG GCC 
Amino acid H G N D P L A 
        
IPMS_mod:        
DNA codon CGC GAC AAC GAC CCA CTG ACC 
Amino acid R D N D P L T 
a The partial IPMS amino acid sequence from position 529 to 535 and its respective DNA 
codons are shown. 
b Mutated nucleotides and amino acids with respect to wild-type IPMS are in boldface. 
 
Table 5. Specific 2-isopropylmalate synthase activities and L-leucine accumulation of 
C. glutamicum wild type and different plasmid-based L-leucine producers in shake 
flask cultivations in CGXII minimal medium with 4% (w/v) glucosea,b.  
Strain 
 
Specific IPMS activity 
(µmol min-1 mgprotein-1) 
 L-leucine titerd 
(mM) 
C. glutamicum 
wild type 
 
0.06 ± 0.01 
 
0 
C. glutamicum 
pAN6-leuA_wt 
 
0.59 ± 0.02 
 
0.8 ± 0.1 
B018 
 
0.03 ± 0.01c 
 
7.8 ± 2.0 
C. glutamicum 
pAN6-leuA_B018 
 
0.63 ± 0.04 
 
40.7 ± 0.4 
C. glutamicum 
pAN6-leuA_mod 
 
0.21 ± 0.01 
 
26.1 ± 0.2  
a Strains carrying plasmids were induced with 0.1 mM IPTG. 
b All data represent mean values with standard deviations obtained from at least three 
independent measurements with different crude extracts. 
c Reduction of IPMS activity in B018 compared to C. glutamicum wild type is attributed to 
attenuation of leuA due to elevated L-leucine concentrations (Pátek et al., 1994). 
d L-Leucine titers represent maximal values reached after 32 h at the latest.  
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Table 6. Catalytic characteristics (KM and Ki values) of 2-isopropylmalate synthase 
from C. glutamicum wild type (IPMS_wt) and strain B018 (IPMS_B018), as well as of 
constructed IPMS_moda,b. 
 IPMS_wt  IPMS_B018  IPMS_mod 
K
M
 2-ketoisovalerate (μM) 6.4 ± 0.1  10.0 ± 0.2  12.0 ± 0.2 
K
M
 acetyl-CoA (μM) 9.6 ± 0.4 
 
9.7 ± 0.4  12.8 ± 0.7 
K
i  
L-leucine (mM)
 0.4 ± 0.1 
 >40 (feedback-
resistant)c  
>40 (feedback-
resistant)c 
a Cells were cultivated in shake flasks using CGXII minimal medium with 4% (w/v) glucose. 
b All data given are mean values with standard deviations obtained from at least three 
independent measurements with different crude extracts. 
c Feedback-resistance was confirmed for concentrations up to 40 mM L-leucine. 
 
3.2 Relevance of the repressor LtbR for L-leucine synthesis 
The transcriptional regulator LtbR was shown to repress expression of leuCD and leuB in the 
presence of high L-leucine concentrations (Brune et al., 2007). Therefore, ltbR was deleted in 
the wild type to increase the expression of leuCD and leuB and the resulting strain ΔltbR was 
transformed with pAN6-leuA_B018. The leuCD genes encode 3-isopropylmalate 
dehydratase (IPMD). In strain C. glutamicum ΔltbR, an IPMD activity of                        
0.79 ± 0.06 µmol min-1 mgprotein-1 was measured, which corresponds to a 13-fold increase in 
comparison to the wild type (0.06 ± 0.01 µmol min-1 mgprotein-1). Strain C. glutamicum ΔltbR 
showed slightly reduced growth (0.38 ± 0.01 h-1) in comparison to the wild type but no           
L-leucine accumulation, whereas C. glutamicum ΔltbR with pAN6-leuA_B018 produced 
43.4 ± 1.1 mM L-leucine, which is approximately 10% more than wild-type C. glutamicum 
with pAN6-leuA_B018. As an additional control of this effect of the deletion of ltbR, also               
L-leucine accumulation using the other feedback-resistant IPMS_mod in C. glutamicum ΔltbR 
was tested. With 32.6 ± 0.2 mM L-leucine produced in shake flask experiments, 
overexpression of pAN6-leuA_mod in C. glutamicum ΔltbR showed a significantly higher                 
L-leucine yield than when expressed in the wild-type background (26.1 ± 0.2 mM).  
Consequently, C. glutamicum ΔltbR was used for further studies. 
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3.3 Construction of strains for increased leuA expression 
3.3.1 Exchange of the native leuA promoter and its attenuator 
In addition to the activity control of leuA-encoded IPMS, leuA expression is controlled by 
attenuation (Mentz et al., 2013; Pátek et al., 1994). In order to abolish premature termination 
of transcription, the native leuA promoter region and the attenuator sequence encoding the 
leader peptide were replaced by the strong promoter of the elongation factor TU (Ptuf) 
(Becker et al., 2005). Since several attempts of a direct replacement failed, leuA was first 
deleted together with its entire promoter region in C. glutamicum ΔltbR to generate the 
leucine-auxotrophic strain C. glutamicum ΔltbR ΔleuA. This strain was transformed with 
pK19mobsacB-Ptuf-leuA_B018 carrying the leuA_B018 gene under the control of Ptuf and the 
native ribosome-binding site of the tuf gene. By selection for regain of growth on leucine-free 
minimal medium, the requested strain was obtained and the correct integration verified by 
sequencing. This strain, MV-Leu20, accumulated approximately 20 mM L-leucine within 24 h 
in CGXII-glucose (Figure 4). The IPMS enzyme activity of strain MV-Leu20 was 
0.09 ± 0.01 µmol min-1 mgprotein-1, corresponding to a 50% increase compared to the activity of 
the wild type. Although the increase was lower than expected, replacement of the leuA 
leader region by Ptuf had a significant positive influence on product formation.  
 
3.3.2 Integration of a second leuA copy 
Since the IPMS enzyme activity was still quite low in strain MV-Leu20, a second copy of                 
Ptuf-leuA_B018 was integrated into the ΔltbR locus of MV-Leu20. The resulting strain                       
MV-Leu20 ΔltbR::Ptuf-leuA_B018 had an IPMS activity of 0.18 ± 0.01 µmol min-1 mgprotein-1 
and L-leucine accumulation was increased by approximately 25% to a titer of 26.4 ± 1.0 mM. 
Both strains MV-Leu20 and MV-Leu20 ΔltbR::Ptuf-leuA_B018 were used for further 
improvements of L-leucine production. 
 
3.4 Balancing precursor supply and metabolic flux towards L-leucine 
3.4.1 Use of feedback-resistant acetohydroxyacid synthase  
The specific IPMS activity in the strain MV-Leu20 ΔltbR::Ptuf-leuA_B018 was almost twice as 
high as the glucose uptake rate of C. glutamicum of approximately 0.1 µmol min-1 mgprotein-1. 
This uptake rate is in accordance with the value given by Frunzke et al. (2008) for the wild-
type strain. Therefore, it was intended to increase the precursor supply, which was already 
achieved in L-valine producers by increasing acetohydroxyacid synthase (AHAS) activity 
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(section 1.4). To this end, the ilvN gene encoding the regulatory subunit of AHAS was 
exchanged in MV-Leu20 and MV-Leu20 ΔltbR::Ptuf-leuA_B018 by a variant encoding IlvN_fbr 
carrying amino acid exchanges G20D, I21D, and I22F (Elišáková et al., 2005). The resulting 
strain originating from MV-Leu20, MV-ValLeu33, produced approximately 33 mM L-leucine 
and 30 mM L-valine after 28 h cultivation in CGXII-glucose (Figure 4). The strain originating 
from MV-Leu20 ΔltbR::Ptuf-leuA_B018 produced up to 55 mM L-leucine and just 
approximately 8 mM L-valine (Figure 4). The latter strain was designated MV-Leu55.  
 
3.4.2 Analysis of limitations of L-leucine production in strain MV-Leu55 
The strain comparison and the strong increase of L-leucine obtained showed that both, 
improved precursor supply (“push”) and increased IPMS activity to redirect metabolic flux 
towards L-leucine instead L-valine (“pull”), offer potential for a further increase. However, 
attempts to integrate a third copy of the construct Ptuf-leuA_B018 into MV-Leu55 failed. 
Plasmid-based expression of leuCD, leuB, ilvE and brnFE in MV-Leu55 did not yield higher 
L-leucine titers, and only traces of 2-ketoisocaproate (KIC) were detected in culture 
supernatants (data not shown). This suggests that the activities of the proteins encoded by 
these genes are not limiting L-leucine production in the MV-Leu55 strain background. 
Interestingly, overexpression of leuA_B018 via plasmid pAN6-leuA_B018 in 
C. glutamicum ΔltbR ilvN_fbr yielded only approximately 45 mM L-leucine, which is 10 mM 
less than using two copies of leuA_B018 under control of the Ptuf promoter (data not shown). 
Besides this, also a deletion of brnQ, encoding the importer for all three BCAAs (Tauch et al., 
1998), showed no effect in MV-Leu55 by preventing a possible re-uptake of L-leucine from 
the supernatant (data not shown). An undesired characteristic of MV-Leu55 was the 
formation of L-valine as a by-product. Therefore, avtA was deleted in MV-Leu55 since the 
encoded transaminase AvtA has the highest activity for L-valine formation (Marienhagen et 
al., 2005). However, no difference in product and by-product accumulation was found (data 
not shown).  
 
3.4.3 Analysis of the growth behavior of MV-Leu55 
Another characteristic of strain MV-Leu55 was that it exhibited two different growth phases: 
In the first 10 h a growth rate of about 0.18 h-1 was observed, which decreased to 
approximately 0.09 h-1 between 10 h and 32 h (Figure 4). This led to a prolonged cultivation 
time of up to 52 h to reach maximal L-leucine titers and consequently to a reduction in 
volumetric productivity. It was investigated if the reduced growth rate in the second phase 
was due to a negative effect of increased L-leucine concentrations on growth. Addition of 
40 mM L-leucine to strain MV-Leu55 right from the beginning of the cultivation did not change 
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its growth behavior or productivity (data not shown), showing that other, yet unknown 
reasons are responsible for the bi-phasic growth behavior.  
 
 
A       B 
 
 
 
 
 
 
 
C       D 
 
 
 
 
 
 
Figure 4. Comparison of the C. glutamicum strains wild type (), MV-Leu7 (), MV-
Leu20 
(), MV-ValLeu33 (), and MV-Leu55 () during cultivation in shake flasks with CGXII 
minimal medium and 4% (w/v) glucose.  
Growth (A), glucose consumption (B), L-leucine formation (C), and L-valine formation (D) are 
shown. The data represent mean values and standard deviations obtained from three 
independent cultivations. 
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3.5 Genome wide gene expression analysis  
In order to confirm the increased expression of genes responsible for L-leucine-biosynthesis 
and to search for additional targets for strain improvement, comparative transcriptome 
analyses were performed with DNA microarrays. Strain MV-Leu55 was compared both with 
C. glutamicum wild type and with strain MV-Leu20. The experiments revealed 15 strongly 
differentially expressed genes (ratio of medians < 0.25 or > 4.0, p-value < 0.05) in at least 
one of the two comparisons (Table 7). As expected, leuA, leuB, and leuCD showed 
significant upregulation (factor 4-9) when comparing strain MV-Leu55 with the wild type, 
whereas the comparison of MV-Leu55 with MV-Leu20 showed most notably an upregulation 
of leuA. In addition, the brnFE genes, encoding an exporter of branched-chain amino acids 
(Kennerknecht et al., 2002), was upregulated in strain MV-Leu55, apparently as a 
consequence of increased cytosolic L-leucine concentrations to enhance its export by BrnFE. 
Most prominent was the expression change of the gene cg3022, which was more than 14-
fold and 8-fold upregulated in MV-Leu55 as compared to C. glutamicum wild type or                 
MV-Leu20, respectively. The amino acid sequence of Cg3022 shares significant similarity to 
the C-terminal regulatory domain of IPMS (http://toolkit.tuebingen.mpg.de/hhpred). When 
cg3022 was deleted in MV-Leu55, there was no change of the L-leucine titer, but the L-valine 
titer increased from about 8 mM to 19.3 ± 0.7 mM. Thus, the protein encoded by cg3022 
appears to be involved somehow in the synthesis of BCAAs, but is not necessary to obtain 
high L-leucine formation. No obvious additional targets for the improvement of L-leucine 
biosynthesis could be identified. Therefore, other strategies to improve productivity and 
decrease formation of by-products of strain MV-Leu55 were used.  
Table 7. Differentially expressed genes in transcriptome comparisons of MV-Leu55/                           
C. glutamicum wild type and MV-Leu55/MV-Leu20 using DNA microarray                
experimentsa,b.  
Gene  Annotation  
MV-Leu55 /                    
wild type 
relative           p-
mRNA level   value 
 
MV-Leu55 /                  
MV-Leu20 
relative           p-
mRNA level   value 
 
cg0286 
  
putative membrane 
protein, conserved 
  
0.14 
 
0.015 
  
0.16 
 
0.052 
cg3427  parA1, ATPase involved 
in chromosome 
partitioning 
 0.14 0.020  0.92 0.136 
cg0791  pyc, pyruvate 
carboxylase 
 0.15 0.005  0.54 0.125 
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Gene  Annotation 
 MV-Leu55 /                    
wild type 
relative           p-
mRNA level   value 
 MV-Leu55 /                  
MV-Leu20 
relative           p-
mRNA level   value 
         
cg1364  atpF, F1F0-ATP synthase 
b-subunit of F0 part 
 0.15 0.019  0.98 0.463 
cg1366  atpA, F1F0-ATP synthase 
α-subunit of F0 part 
 0.15 0.040  0.94 0.372 
cg2184  ATPase component of 
peptide ABC-type 
transport system, 
contains duplicated 
ATPase domains 
 0.41 0.002  0.19 0.010 
cg1419  putative Na+-dependent 
transporter, bile acid:Na+ 
symporter BASS family 
 4.24 0.019  0.68 0.008 
cg2636  catA1, catechol 1,2-
dioxygenase 
 4.33 0.013  4.84 0.012 
cg0303  leuA, 2-isopropylmalate 
synthase 
 4.86 0.002  3.10 0.098 
cg1487  leuC, 3-isopropylmalate 
dehydratase large 
subunit 
 6.83 0.004  1.92 0.174 
cg0315  brnEc, branched-chain 
amino acid exporter, 
small subunit 
 7.05 0.034  1.42 0.296 
cg1488  leuD, 3-isopropylmalate 
dehydratase small 
subunit 
 7.64 0.022  1.00 0.470 
cg1658  putative permease of the 
major facilitator 
superfamily 
 8.77 0.046  0.84 0.025 
cg1453  leuB, 3-isopropylmalate 
dehydrogenase 
 9.45 0.005  1.00 0.320 
cg3022  putative acetyl-CoA 
acetyltransferase, 
conserved 
 14.00 0.002  8.61 0.005 
a Genes were chosen which fulfilled the criteria relative mRNA level > 4 or < 0.25 in at least 
one of the two comparisons. 
b Data of each comparison represent mean values of three independent DNA microarray 
experiments starting from independent cultures grown in CGXII minimal medium + 4% (w/v) 
glucose. 
c Relative mRNA levels of cg0314 (brnF, annotated as branched chain amino acid exporter, 
large subunit) were 2.50 (p-value 0.006) and 1.60 (p-value 0.048) for comparison of                          
MV-Leu55/wild type and MV-Leu55/MV-Leu20, respectively. 
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3.6 Optimizing productivity of MV-Leu55 
3.6.1 Increase of glucose uptake 
It was demonstrated that deletion of the transcriptional regulator IolR derepresses genes of 
inositol metabolism in C. glutamicum (Klaffl et al., 2013), including iolT1 encoding the PTS-
independent inositol transporter IolT1 which also catalyzes glucose uptake (Ikeda et al., 
2011; Lindner et al. 2011). Assuming that an increased glucose uptake capacity could 
improve growth and production properties of MV-Leu55, iolR was deleted. The resulting 
strain MV-Leu55 ΔiolR exhibited an increased and constant growth rate of 0.2 h-1. The 
glucose uptake rate was increased by 43% from 53 ± 3 nmol-1 min-1 mgCDW-1 in strain                 
MV-Leu55 up to 76 ± 1 nmol-1 min-1 mgCDW-1 in strain MV-Leu55 ΔiolR. Despite the fact that 
the L-leucine titer was decreased to approximately 40 mM and at the same time the L-valine 
titer was increased to approximately 20 mM (Figure 5), volumetric productivity was strongly 
increased by about 40% from 1.04 ± 0.03 mmol l-1 h-1 to 1.38 ± 0.02 mmol l-1 h-1 (Figure 6). 
Besides increased productivity, MV-Leu55 ΔiolR showed other benefits: growth and product 
accumulation turned out to be exhibiting exceptional reproducibility, probably due to a well-
balanced precursor supply based on increased sugar uptake. However, compared to its 
precursor strain MV-Leu55, it showed increased by-product formation and a lower L-leucine 
titer. The added total concentration of L-valine and L-leucine remained the same as in              
MV-Leu55. 
 
3.6.2 Integration of a third leuA copy 
It was assumed that the flux towards KIV is increased in MV-Leu55 ΔiolR and IPMS activity 
seems to be insufficient to convert this precursor completely to L-leucine. Therefore, another 
attempt was made to integrate a third copy of Ptuf-leuA_B018 into the intergenic region 
between cg1121 and cg1122 to reduce L-valine formation in favor of increased L-leucine titer 
and yield. The intergenic region between these divergently organized genes in the genome 
of C. glutamicum was successfully used in the past for integration of genes or operons 
(Blombach et al., 2009). In the MV-Leu55 ΔiolR background, integration of a third copy of 
Ptuf-leuA_B018 was achieved, perhaps due to the increased glucose uptake capacity of 
strain MV-Leu55 ΔiolR. As expected, the resulting strain MV-LeuF1 showed an increased                
L-leucine titer of approximately 45 mM, while formation of L-valine was reduced to 15 mM 
(Figure 5). Compared to strains with two copies of Ptuf-leuA_B018, the IPMS activity of             
MV-LeuF1 was increased by about 10% to 0.20 ± 0.01 µmol min-1 mgprotein-1 (Table 8). 
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A       B 
 
 
 
 
 
 
C       D 
 
 
 
 
 
 
 
Figure 5. Comparison of the C. glutamicum strains MV-Leu55 (), MV-Leu55 ΔiolR (), 
and MV-LeuF1 () during cultivation in shake flasks with CGXII minimal medium and 
4% (w/v) glucose.  
Growth (A), glucose consumption (B), L-leucine formation (C), and L-valine formation (D) are 
shown. The data represent mean values and standard deviations obtained from three 
independent cultivations. 
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Table 8. Specific 2-isopropylmalate synthase activities of plasmid-free L-leucine 
producers with different copy numbers of the module Ptuf-leuA_B018 obtained in 
shake flask cultivations in CGXII minimal medium with 4% (w/v) glucosea.   
Strain Number of                                      
Ptuf-leuA_B018 copies 
Specific IPMS activity                       
(µmol min-1 mgprotein-1) 
MV-Leu20 1 0.09 ± 0.01 
MV-Leu20 ΔltbR::Ptuf-leuA_B018 2 0.18 ± 0.01 
MV-LeuF1 3 0.20 ± 0.01 
a All data represent mean values with standard deviations obtained from at least three 
independent measurements with different crude extracts. 
 
 
3.7 Reduction of citrate synthase activity 
As strain MV-LeuF1 was not in shortage of the IPMS substrate KIV due to the observed               
L-valine accumulation, it was decided to increase the supply of the second IPMS substrate 
acetyl-CoA. To this end, it was made use of the previous observation that the reduction of 
citrate synthase activity in C. glutamicum is beneficial for L-lysine production and also leads 
to an increase in the intracellular concentration of acetyl-CoA (van Ooyen et al., 2012). 
Consequently, the two promoters in front of the gltA gene encoding citrate synthase 
(van Ooyen et al., 2011), were replaced by the weaker promoter PdapA-L1 (Vašcicová et al., 
1999) in MV-LeuF1, which reduces the citrate synthase activity to 16% of the wild-type 
activity (van Ooyen et al., 2012). The resulting strain MV-LeuF2 was comparable to                   
MV-LeuF1 with respect to growth, but L-leucine formation was increased to 52.0 ± 1.9 mM 
and L-valine formation was strongly decreased to 4.6 ± 0.1 mM. These results confirmed the 
successful redirecting of the KIV flux from L-valine towards L-leucine due to increased  
acetyl-CoA supply. The L-leucine volumetric productivity of MV-LeuF2 was increased to 
1.73 ± 0.07 mmol l-1 h-1 (Figure 6). 
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Figure 6. Maximal values of L-leucine formation, L-valine formation, and volumetric 
productivity obtained for the indicated L-leucine producing strains in shake flask 
experiments.  
L-Leucine titers were reached after 32 h at the latest, except for strain MV-Leu55 which 
reached the maximal concentration after 52 h. The data represent mean values and standard 
deviations obtained from three independent cultivations.  
3.8 Relationship between growth rate and L-leucine titer 
Since the precursors for building blocks are used for biomass and product formation as well, 
the growth rates of the different L-leucine production strains were compared (Table 9). 
Indeed, with the exception B018, there is a clear correlation of increasing L-leucine titer with 
decreasing growth rate. Strain B018 was obtained by undirected mutagenesis and is likely to 
carry additional mutations which are disadvantageous for growth. The observed correlation 
of increasing L-leucine formation with decreasing growth is a strong indication for a limited 
supply of precursors. This agrees with the positive effect on the growth rate when the sugar 
uptake is increased by iolR deletion (Ikeda et al., 2011).  
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Table 9. Growth rates and L-leucine titers obtained with the indicated strains in shake 
flask cultivations in CGXII minimal medium with 4% (w/v) glucosea. 
Strain  Growth rate                           (h-1) 
L-leucine titer               
(mM) 
C. glutamicum wild type 
 
0.44 ± 0.01 
 
0 
B018 
 
0.23 ± 0.01 
 
7.8 ± 2.0 
ΔltbR 
 
0.38 ± 0.01 
 
0 
MV-Leu7 
 
0.38 ± 0.01 
 
6.9 ± 0.5 
MV-Leu20 
 
0.31 ± 0.01 
 
21.5 ± 1.2 
MV-Leu20 ΔltbR::Ptuf-leuA_B018 
 
0.25 ± 0.01  
 
26.4 ± 1.0 
MV-ValLeu33 
 
0.21 ± 0.01 
 
32.9 ± 2.7 
MV-Leu55 
 
0.09 - 0.18b 
 
53.9 ± 1.5 
MV-Leu55 ΔiolR 
 
0.20 ± 0.01 
 
38.7 ± 0.6 
MV-LeuF1 
 
0.20 ± 0.01 
 
44.0 ± 0.4 
MV-LeuF2 
 
0.19 ± 0.01 
 
52.0 ± 1.9 
a The data represent mean values and standard deviations obtained from three independent 
cultivations. 
b MV-Leu55 showed an initial growth rate of approximately 0.18 h-1 in the first 10 h, which 
decreased to approximately 0.09 h-1 between 10 h and 32 h. 
 
All relevant metabolic engineering steps performed in the different plasmid-free L-leucine 
producers of C. glutamicum up to MV-LeuF2 are summarized and depicted in Figure 7. 
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Figure 7. Schematic representation of the L-leucine biosynthesis pathway of 
C. glutamicum and of the metabolic engineering steps performed in this work.  
Enzymes and their corresponding genes relevant for this work are shown in boxes. 
Regulatory proteins are shown in cycles. Lines with “+” indicate activation of gene 
expression; “-“ indicates repression of gene expression (solid lines) or indicates feedback-
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inhibition/transcription attenuation (dashed lines). “Leu”, “Val”, and Ile” indicate the presence 
of L-leucine, L-valine, and L-isoleucine, respectively. Deletion of genes and the respective 
proteins as well as abolishment of feedback-inhibition and transcription attenuation are 
indicated by “X”. Metabolic engineering steps, i.e. promoter exchanges and integration of 
genes encoding feedback-resistant enzyme variants, are highlighted in grey. Thick arrows 
indicate increased metabolic fluxes. Abbreviations: AHAS, acetohydroxyacid synthase; 
AHAIR, acetohydroxyacid isomeroreductase; BCAA-E, branched-chain amino acid exporter 
(BrnFE); BCAAT, branched-chain amino acid transaminase IlvE; CS, citrate synthase; 
DHAD, dihydroxyacid dehydratase; fbr, feedback-resistant; Glucose-6-P,                     
glucose-6-phosphate; IPMD, 3-isopropylmalate dehydratase; IPMDH, 3-isopropylmalate 
dehydrogenase; IPMS, 2-isopropylmalate synthase; Lrp, leucine-responsive protein; LtbR, 
leucine and tryptophane biosynthesis regulator; P, promoter; PTS, phosphotransferase 
system; TCA, tricarboxylic acid cycle. 
 
3.9 Batch and fed-batch cultivations 
3.9.1 Test fermentations 
Strains MV-Leu55 and MV-LeuF1 were characterized in preliminary batch fermentations 
(pH 7.2). MV-LeuF1 showed a production pattern similar to that obtained in shake flask 
experiments (Table 10). In contrast, MV-Leu55 exhibited slow growth (μ = 0.12 ± 0.2 h-1) and 
significantly increased L-valine formation as a by-product (12.8 ± 0.6 mM) at the cost of 
reduced L-leucine accumulation (34.4 ± 0.9 mM). Notably, the slow growth of MV-Leu55 was 
constant (data not shown), without further decrease during proceeding cultivation time as 
obtained in shake flask cultivations (Figure 4). Nevertheless, the main advantage of MV-
Leu55 - reaching the highest titer of all strains in shake flask cultivations - was absent in 
bioreactor fermentations. Therefore, it was decided to use MV-LeuF1 and MV-LeuF2 for 
further improvement of fermentation conditions.  
 
3.9.2 Optimizing fermentation conditions 
Strains MV-LeuF1 and MV-LeuF2 were characterized in fed-batch cultivations in order to 
determine the influence of different process parameters on productivity and to analyze the 
behavior of the strains under such controlled conditions. In addition to L-valine, also L-alanine 
and L-lysine accumulated as by-products in initial fed-batch-experiments at pH 7.2 to 
concentrations exceeding 24 mM and 10 mM, respectively, especially in the fed-batch phase. 
To determine the optimal pH for L-leucine production, cultivations were performed at pH 6.5, 
7.2, and 8.0. At pH 8.0, cells stopped growing when they reached an OD600 of 4-5 and 
therefore this pH was not studied any further (data not shown). Table 10 shows product and 
by-product formation of MV-LeuF1 at pH values of 6.5 and 7.2. Cells showed similar growth 
rates at both pH values, but product and by-product formation differed. In comparison to 
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pH 7.2, L-lysine secretion was increased at pH 6.5 by approximately 45% to 14 mM, but the 
L-valine and L-alanine titers were reduced by 65% and 30% to approximately 6 mM and 
17 mM, respectively. Moreover, L-leucine formation was increased at pH 6.5 in the batch 
phase by approximately 20% compared to pH 7.2 (from 33 mM to 40 mM). Based on these 
results, the subsequent fermentations were performed at pH 6.5. Furthermore, the feed 
solution, which originally contained only 50% (w/v) glucose, was supplemented with 4% (w/v) 
ammonium sulfate, as increasing concentrations of KIC were detected in the culture 
supernatant at later time points of the fed-batch process, indicating nitrogen limitation.   
 
 
Table 10. Influence of pH values 6.5 and 7.2 on product and by-product formation in 
fed-batch fermentations of strain MV-LeuF1a,b. 
                                              Batch phase 
 pH 6.5  pH 7.2 
Cultivation time (h)c 25.0  25.0 
L-Leucine (mM) 39.5 ± 0.1  32.8 ± 0.1 
By-products    
      L-Valine (mM) 
      L-Alanine (mM) 
      L-Lysine (mM) 
5.1 ± 0.1 
2.7 ± 0.1 
4.7 ± 0.0 
 
10.8 ± 0.3 
3.8 ± 0.6 
3.9 ± 0.1 
                                              Batch phase + Feed phase 
    pH 6.5  pH 7.2 
Cultivation time (h) 54.0  54.0 
L-leucine (mM) 127.4 ± 2.1d  128.5 ± 11.5d 
By-products   
  
 
      L-Valine (mM) 
     L-Alanine (mM) 
     L-Lysine (mM) 
5.9 ± 0.4 
16.8 ± 1.0 
13.9 ± 1.0 
 16.8 ± 1.7 
24.4 ± 0.1 
9.5 ± 0.1 
a Fed-batch fermentations were run with 600 ml (modified) CGXII minimal medium                                        
with 4% (w/v) glucose. Feed phase was performed with feed solution containing 50% (w/v)                        
glucose. The overall process was run for 54 h.   
b The values given are the average data with standard deviations from two independent fed-
batch fermentations. 
c The growth rates in batch phase for pH 6.5 and pH 7.2 were 0.15 ± 0.01 h-1 and 
0.14 ± 0.01 h-1, respectively. 
d A few mmol of the L-leucine precursor KIC were also detected in the supernatants, 
indicating nitrogen source limitation. 
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3.9.3 Characteristics of fed-batch cultivations of MV-LeuF1 and MV-LeuF2 
Using the optimized conditions described above, three independent fed-batch cultivations 
were performed with each of the strains MV-LeuF1 and MV-LeuF2. Representative 
experiments are shown in Figure 8 and Figure 9, respectively; the additional cultivations are 
presented in Figure 10. The average process data of all three fed-batch cultivations of          
MV-LeuF1 and MV-LeuF2 are listed in Table 11.  
 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Representative fed-batch fermentation of MV-LeuF1.  
Panel A shows growth (dashed line), oxygen partial pressure (pO2) representing the 
dissolved oxygen saturation (solid line), and absolute CO2 concentration (dashed/dotted 
line). Panel B shows the formation of L-leucine (), L-valine (), L-alanine (), and L-lysine 
(). The Multifors bioreactor was filled with 500 ml modified CGXII medium containing 
4% (w/v) glucose for the batch phase. In the feed phase, an aqueous feeding solution 
containing 50% glucose (w/v) and 4% (w/v) ammonium sulfate was used. The pH was kept 
constant at value 6.5 by addition of 3 M HCl or 3 M NaOH. Decreasing pO2 and rising CO2 
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signals were due to the respiratory activity of the growing cells. A sudden rise of pO2 in the 
first hours of the cultivation (here after approximately 10 h and 16 h) is due to an increase of 
the stirrer speed in order to maintain pO2 > 30%. The batch phase ended after 22.5 h due to 
depletion of glucose as indicated by an increase of pO2 to > 80%, followed by the start of the 
feed phase. The automatic feeding program created a “sawtooth” pattern in the feed phase: 
a sudden rise of pO2 to a value of > 80% indicated the depletion of glucose and triggered the 
addition of feed solution. This in turn led to a drop of pO2 due to the restarting metabolic 
activity of the cells. The cultivation was stopped after 56 h. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 9. Representative fed-batch fermentation of MV-LeuF2.  
Panel A shows growth (dashed line), oxygen partial pressure (pO2) representing the 
dissolved oxygen saturation (solid line), and absolute CO2 concentration (dashed/dotted 
line). Panel B shows the formation of L-leucine (), L-valine (), L-alanine (), and L-lysine 
(). For details see legend of Figure 8. The batch phase ended/feed phase started after 
24.5 h. The cultivation was stopped after 56 h. 
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Strain MV-LeuF1 produced 151.2 ± 5.1 mM (approximately 20 g l-1) L-leucine within 52 h with 
a molar product yield (mol L-leucine/mol glucose) of 0.253 ± 0.009 in the feed phase and 
0.233 ± 0.005 in the overall process. The volumetric productivity was 3.9 ± 0.1 mmol l-1 h-1 in 
the feed stage and 2.9 ± 0.1 mmol l-1 h-1 in the overall process. The by-product 
concentrations were relatively small: 7.5 ± 0.4 mM L-valine, 11.7 ± 1.2 mM L-lysine, and 
20.2 ± 4.3 mM L-alanine in the overall process. Strain MV-LeuF2 reached the same final       
L-leucine titer of 151.9 ± 12.7 mM, but the concentrations of the by-products L-valine 
(5.8 ± 1.2 mM) and L-alanine (11.0 ± 1.0 mM) were lower, resulting in an increased molar 
product yield of 0.298 ± 0.013 mol per mol of glucose in the feed phase and 
0.263 ± 0.012 mol per mol of glucose in the overall process. The volumetric productivity of 
MV-LeuF2 in the feed phase (4.3 ± 0.4 mmol l-1 h-1) and in the overall process 
(3.1 ± 0.3 mmol l-1 h -1) was also higher than that of strain MV-LeuF1.  
When the process time in the fed-batch cultivations exceeded approximately 56 h, the                     
L-leucine concentrations increased only slightly with both strains (Figure 8 and Figure 9). 
This effect could be explained by the beginning precipitation of the product L-leucine, which 
is very hydrophobic. Its solubility in water was reported to be 24.3 g l-1 (Dawson, 1986). After 
72 h of cultivation, thick foam and white powder on top of the cultures was observed, which 
was found to be almost pure L-leucine without other contaminating amino acids. The highest 
concentration of soluble L-leucine at this point was 181 mM (23.7 g l-1), which corresponds 
quite exactly to the solubility value given above.  
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Table 11. Results of fed-batch cultivationsa of strains MV-LeuF1 and MV-LeuF2 
including maximum L-leucine and by-product concentrations as well as specific molar 
yields and volumetric productivities of batch phase, feed phase, and the overall 
processb.                                                 
 
Batch phasec  Feed phase  Overall process 
(Batch + Feed 
phase) 
 
 
MV-
LeuF1 
MV-
LeuF2 
 MV-
LeuF1 
MV-
LeuF2 
 MV- 
LeuF1 
MV-
LeuF2 
 
Cultivation time 
(h) 
 
23.75 
± 
1.25 
 
24.00 
± 
1.50 
  
28.25 
± 
1.25 
 
25.00 
± 
2.25 
  
52.00 
± 
0.50 
 
50.00 
± 
2.00 
L-Leucine 
(mM) 
39.0 
± 
1.1 
42.9 
± 
2.1 
 112.2 
± 
6.0 
109.0 
± 
11.5 
 151.2 
± 
5.1 
151.9 
± 
12.7 
By-products:         
L-Valine 
(mM) 
 
 
L-Alanine 
(mM) 
 
 
L-Lysine 
(mM) 
5.1 
± 
0.7 
 
2.9 
± 
0.7 
 
3.3 
± 
0.3 
4.2 
± 
0.4 
 
2.1 
± 
0.2 
 
4.1 
± 
0.6 
 2.4 
± 
0.3 
 
17.3 
± 
4.7 
 
8.4 
± 
1.6 
1.6 
± 
1.6 
 
8.9 
± 
1.2 
 
7.6 
± 
1.8 
 7.5 
± 
0.4 
 
20.2 
± 
4.3 
 
11.7 
± 
1.2 
5.8 
± 
1.2 
 
11.0 
±              
1.0 
 
11.7 
± 
1.3 
Molar product 
yield 
(mol L-leucine/ 
mol glucose) 
0.176 
± 
0.005 
0.194 
± 
0.010 
 0.253 
± 
0.009 
0.298 
± 
0.013 
 0.233 
± 
0.005 
0.263 
± 
0.012 
Volumetric 
productivity 
(mmol L-leucine/ 
(l x h)) 
1.7 
± 
0.1 
1.8 
± 
0.2 
 3.9 
± 
0.1 
4.3 
± 
0.4 
 2.9 
± 
0.1 
3.1 
± 
0.3 
a Fed-batch fermentations were run at a constant pH of 6.5 starting with 500 ml (modified) 
CGXII minimal medium + 4% (w/v) glucose. Feed phase was performed with feed solution 
containing 50% (w/v) glucose and 4% (w/v) ammonium sulfate. Overall process was run                                                     
for 48-52 h. 
b Mean values and standard deviations from three independent fed-batch cultivations of each 
strain are shown. 
c The growth rates in batch phase for MV-LeuF1 and MV-LeuF2 were 0.19 ± 0.02 h-1 and 
0.15 ± 0.02 h-1, respectively. 
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IVA      IVB 
 
 
 
 
Figure 10.  Fed-batch fermentations of MV-LeuF1 (I+II) and MV-LeuF2 (III+IV).  
Panel A shows growth (dashed line), oxygen partial pressure (pO2) representing the 
dissolved oxygen saturation (solid line), and absolute CO2 concentration (dashed/dotted 
line). Panel B shows the formation of L-leucine (), L-valine (), L-alanine (), and L-lysine 
(). For details see legend of Figure 8 and Figure 9. 
 
 
 
3.10  Production of 2-ketoisocaproate 
3.10.1 Consequences of ilvE deletion at elevated L-leucine production  
The next aim was to test if it was possible to turn L-leucine producers into producers of           
2-ketoisocaproate (KIC). IlvE is the main transaminase involved in the conversion of KIC,           
2-ketoisovalerate (KIV), and 2-keto-3-methylvalerate (KMV) into L-leucine, L-valine and         
L-isoleucine, respectively (Radmacher et al., 2002). The deletion of ilvE in C. glutamicum 
leads to auxotrophies for L-leucine and L-isoleucine, but not L-valine because this amino acid 
can be formed by transamination of KIV via the avtA-encoded enzyme (Marienhagen et al., 
2005). It was expected that the deletion of the gene ilvE in an L-leucine producer would lead 
to accumulation of this precursor. The wild-type strain, the C. glutamicum ΔilvE strain 
(supplemented with 1 mM L-leucine and 1 mM L-isoleucine) and the L-leucine producing 
strain C. glutamicum ΔltbR with pAN6-leuA_B018 (induced with 0.1 mM IPTG) were tested in 
shake flask experiments with CGXII-glucose medium for KIC production. None of the strains 
were able to accumulate KIC in detectable concentrations in the supernatant. In a next step, 
C. glutamicum ΔilvE was transformed with the plasmid pAN6-leuA_B018 and tested in 
CGXII-glucose supplemented with 1 mM L-leucine, 1 mM L-isoleucine, and 0.1 mM IPTG. 
This strain accumulated 34.0 ± 1.7 mM KIC in the supernatant, demonstrating that it is easily 
possible to convert a C. glutamicum L-leucine producer into a KIC producer. 
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3.10.2 Reduction of transamination activity in L-leucine producers 
Analogously to the constructed L-leucine production strains, it was intended to design strains 
devoid of plasmids, heterologous genes, and auxotrophies for KIC production. Therefore, the 
aim was to downregulate the activity of IlvE instead of deleting ilvE. Low residual activity of 
IlvE should avoid auxotrophies for L-leucine and L-isoleucine, but still allow the accumulation 
of KIC. To reach this goal, the ATG start codon of ilvE should be exchanged against GTG 
start codon to decrease the translation initiation rate of the ilvE transcript, thereby reducing 
IlvE activity (Figure 11).  
The ATG start codon of ilvE was exchanged against GTG start codon in MV-LeuF1, one 
of the most efficient L-leucine production strains, to yield strain MV-KICF1. Strain MV-KICF1 
was cultivated in CGXII-glucose medium with or without 1 mM L-isoleucine and                      
1 mM L-leucine to monitor KIC accumulation in the supernatant. Remarkably, only the 
addition of L-isoleucine, but not L-leucine, was necessary to provide growth of MV-KICF1 
(data not shown). Supplementation of L-leucine in addition to L-isoleucine for cultivation of 
MV-KICF1 did not alter the growth rate significantly in minimal medium so that addition of    
L-leucine was omitted in the cultivations. The direct ancestor strain of MV-KICF1 (MV-LeuF1) 
and strain SH-KIC20 (Sabine Haas, FZ Jülich) served as references (Figure 11). SH-KIC20 
was constructed also by exchanging the ATG start codon of ilvE against GTG start codon in 
the L-leucine producer MV-Leu20. The results obtained for MV-KICF1 and SH-Leu20 are 
summarized in Table 12. Both SH-KIC20 and MV-KICF1 grew slowly without 
supplementation of L-isoleucine and confirmed that the start codon exchange provides 
residual IlvE activity to enable growth. The poor growth of these strains unfortunately led to 
very low volumetric KIC productivities of approximately 0.35 mmol l-1 h-1. Supplementation of 
L-isoleucine was additionally tested for MV-KICF1 and enabled this strain               
(µ = 0.21 ± 0.01 h-1) to grow similarly to MV-LeuF1 (µ = 0.20 ± 0.01 h-1). The latter strain did 
not produce KIC because it carries the native ilvE gene. SH-KIC20 produced approximately 
19 mM KIC in 49 h, which is comparable to the L-leucine titer achieved with its ancestor 
strain MV-Leu20. Strain MV-KICF1 accumulated approximately 47 mM KIC after 32 h when 
supplemented with L-isoleucine, which corresponds to L-leucine production achieved with 
MV-LeuF1. In contrast, omitting L-isoleucine yielded a maximal KIC concentration of only 
34 mM after 95 h. Since IlvE is the main transaminase for the formation of all three BCAAS, 
accumulation of the other two keto acids KIV and KMV as by-products was expected as well. 
Indeed, accumulation of KMV and KIV was detected in the supernatants of both KIC 
producers. The ancestor strain MV-LeuF1 produced more L-valine as by-product than strain 
MV-Leu20 (Figure 6) so that, as expected, also an increased KIV level could be detected in 
the respective KIC producer MV-KICF1 in comparison to SH-KIC20. Notably, also L-leucine 
was detected in supernatants of the KIC producing strains. Strain MV-KICF1 supplemented 
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with L-isoleucine yielded best values concerning titer (46.7 ± 4.1 mM), yield 
(0.204 ± 0.018 mol per mol of glucose), and productivity (1.41 ± 0.13 mmol l-1 h-1). 
An interesting observation of the shake flask experiments using the KIC producers was 
that KIC concentrations decreased with proceeding cultivation time after they had reached 
the maximal values. Maximal KIC concentration obtained with MV-KICF1 decreased from 
46.7 ± 4.1 mM after 32 h to 41.0 ± 3.4 mM after 48 h. This decrease was not observed for         
L-leucine produced by the respective ancestor production strains. It was assumed that a re-
uptake of the produced KIC into the cells from the supernatant occurred and that KIC was 
taken up by the cells and transaminated, at least partly, to L-leucine. Indeed, L-leucine 
concentrations in supernatants of MV-KICF1 increased moderately from 3.0 ± 0.2 mM after 
32 h to 4.0 ± 0.1 mM after 48 h.  
 
 
A     B     
  
 
 
 
 
 
Figure 11. Growth curves of C. glutamicum strains MV-KICF1 and SH-KIC20 in shake 
flasks with CGXII minimal medium and 4% (w/v) glucose.  
Panel A shows the growth of MV-KICF1 supplemented with 1 mM L-isoleucine () and its 
ancestor strain MV-LeuF1 () as reference (inoculated to initial OD600 = 0.5). Panel B shows 
MV-KICF1 without supplements () and strain SH-KIC20 without supplements () as 
reference (inoculated to initial OD600 = 1). 
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Table 12. Results of shake flask cultivations of strains MV-KICF1 and SH-KIC20 
including growth rates, maximum KIC and by-product concentrations, as well as 
specific molar yields and volumetric productivitiesa,b.                                                 
 
MV-KICF1 
+ 1 mM                              
L-isoleucine 
(32 h) 
 MV-KICF1 
without                           
L-isoleucine 
(95 h) 
 SH-KIC20d  
without                         
L-isoleucine 
(49 h) 
Growth rate (h-1) 0.21 ± 0.01  0.03 ± 0.01  0.08 ± 0.01 
KIC (mM) 46.7 ± 4.1  31.8 ± 2.1  18.8 ± 0.67 
By-productsc:      
      KIV (mM) 
 
      KMV (mM) 
 
      L-leucine (mM) 
13.3 ± 2.2 
 
8.8 ± 1.3 
 
3.0 ± 0.2 
 19.0 ± 4.1 
 
4.9 ± 0.6 
 
10.3 ± 3.1 
 2.6 ± 0.3 
 
8.7 ± 0.1 
 
4.8 ± 0.2 
Molar product yield 
(mol KIC /  
mol glucose) 
0.204 ± 0.018 
 
0.143 ± 0.010 
 
 
0.084 ± 0.001 
Volumetric 
productivity  
(mmol KIC / (l x h)) 
1.41 ± 0.13  0.34 ± 0.02  0.38 ± 0.02 
a Cultivations were run with 50 ml CGXII minimal medium with 4% (w/v) glucose. Addition of 
L-isoleucine is indicated. Cultivation time is shown in parentheses.  
b The values given are the average data with standard deviations from three independent 
cultivations. 
c Concentrations of L-valine and L-isoleucine were below 2 mM. 
d Cultivation of SH-KIC20 supplemented with 1 mM L-isoleucine was not tested. 
 
 
3.10.3 Batch fermentation of MV-KICF1 
To test the possibility for a process scale-up, strain MV-KICF1 was cultivated in bioreactors 
in batch mode (Figure 12). L-Isoleucine (0.3 g l-1) was added to the fermentation medium 
because this strain performed best when supplemented with this amino acid. 
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Figure 12. Batch fermentation of MV-KICF1.  
Growth () as well as formation of KIC (), KMV (), KIV (), and L-leucine () is shown. 
Strain MV-KICF1 was cultivated in Multifors bioreactors filled with 500 ml modified CGXII 
medium containing 4% (w/v) glucose and 0.3 g l-1 L-isoleucine. The pH was kept constant at 
value 7.0 by automatic addition of 3 M HCl or 3 M NaOH. The growth rate was 0.14 ± 0.01 h-
1. No L-isoleucine was detected after 28 h and L-valine concentration was below 1.5 mM. The 
data represent mean values and standard deviations obtained from three independent 
fermentations. 
 
The batch fermentations revealed a production pattern similar to that obtained in shake flask 
cultivations, although lower concentrations of product and by-products were obtained.       
MV-KICF1 produced approximately 35.8 ± 0.3 mM KIC. By-products were 2.2 ± 0.1 mM 
KMV, 4.2 ± 0.3 mM KIV, and 5.1 ± 0.2 mM L-leucine, which meant that the keto acid 
concentrations were clearly decreased in comparison to shake flask cultivations while           
L-leucine concentrations were slightly increased. 
Interestingly, additional feeding of 50% (w/v) glucose resulted in maximal KIC 
concentrations of approximately 50 mM without further increasing. This was accompanied by 
an arrest of growth of the cells and no further consumption of the added glucose (data not 
shown). Possibly, an inhibition of cell metabolism due to elevated KIC concentrations 
occurred. 
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4 Discussion 
L-Leucine is an interesting product with diverse commercial applications explaining the 
demand for strains that can be used for the ecological and economically competitive 
biotechnological production of this amino acid. In this study, potent L-leucine producing 
C. glutamicum strains were constructed by rational design, which achieved high values in 
terms of product titer, yield, and volumetric productivity as well as only low by-product 
formation. An important characteristic of these strains is the absence of auxotrophies, 
heterologous genes, and plasmids, thus preventing conflicts with regulatory restrictions and 
avoiding the use of cost-intensive supplements and antibiotics. These properties make these 
strains highly suitable for industrial application.  
Moreover, the feasibility of easily turning L-leucine production strains into producers of the 
precursor 2-ketoisocaproate (KIC), which also has interesting applications in medicine and 
other fields, was shown. 
 
4.1 IPMS is the key enzyme for L-leucine production 
This work started with the weak L-leucine producing strain B018, which had been created by 
random mutagenesis. The aim was to identify the genes responsible for L-leucine 
accumulation by comparison of genomic data, in this case DNA sequences related to           
L-leucine biosynthesis of B018 with respect to the wild-type strain. The identified target genes 
were supposed to be transferred into the wild type background to create a genetically defined 
and minimally mutated strain. This strategy of “genome-based strain reconstruction” was 
already successfully employed for L-lysine production with C. glutamicum (Ohnishi et al., 
2002). This approach revealed that B018 carries two amino acid exchanges in its leuA-
encoded 2-isopropylmalate synthase (IPMS) with respect to the wild-type sequence. IPMS, 
the first enzyme in specific L-leucine biosynthesis, emerged to be a key player enzyme for           
L-leucine production. The integration of the mutations coding for the respective amino acid 
exchanges into the leuA gene of the wild type (with deleted ltbR gene) indeed led to L-leucine 
production in similar concentrations as achieved with B018. Remarkably, the created strain 
MV-Leu7 exhibited a significantly higher growth rate than B018 (Table 9), leading to an 
increased productivity. Strains achieved by random mutagenesis are often inferior to the wild 
type in properties that are important for a productive industrial application, e.g. growth, sugar 
consumption, or stress tolerance. This is attributed to genome-wide secondary mutations, 
which often have detrimental effects (Ohnishi et al., 2002). Therefore, it is advantageous to 
transfer only beneficial mutations into the wild-type strain by allelic replacement to achieve 
improved performance and increased robustness (Ikeda et al., 2006). The comparison of the 
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rationally designed strain MV-Leu7 and B018 achieved by a random approach demonstrates 
the benefit of this strain reconstruction strategy based on genomic data.  
Transcription of leuA coding for IPMS is controlled by attenuation and IPMS activity is 
subject to feedback-inhibition with a Ki for L-leucine of 0.4 mM (Pátek et al, 1994). This 
mechanism represents the major bottleneck for L-leucine production because it prevents the 
accumulation of amounts of L-leucine exceeding approximately 1 mM. This tight control of the 
L-leucine biosynthesis pathway, also in comparison to the other BCAAs, is emphasized by 
the internal concentrations of the BCAAs in the cell: While there are about 5 mM L-isoleucine 
and 7 mM L-valine, no L-leucine (concentration < 1 mM) is detected in the wild type of 
C. glutamicum (Leyval et al., 2003). L-Leucine has high metabolic costs due to the need of 
two molecules of pyruvate and one molecule of acetyl-CoA (altogether eight carbon atoms) 
to synthesize one molecule of L-leucine (six carbon atoms). It has been reported recently that         
L-leucine is even the metabolically most expensive amino acid in E. coli (Kaleta et al., 2013). 
The maximal theoretical molar yield of L-leucine per glucose was calculated to be 0.6 mol per 
mol of glucose in C. glutamicum with non-growing cells (Stephan Noack, FZ Jülich, personal 
communication). In comparison, the theoretical yields of the other BCAAs L-valine and          
L-isoleucine are higher, i.e. up to 1 mol per mol of glucose (Bartek et al., 2010) and 0.78 mol 
per mol of glucose (Stephan Noack, FZ Jülich, personal communication), respectively. Due 
to the high costs of L-leucine biosynthesis, tight regulation of the starting enzyme IPMS is 
reasonable. Correspondingly, even overexpression of wild-type leuA yielded only very low          
L-leucine titers in the supernatant. In contrast, overexpression of leuA from strain B018 led to 
L-leucine accumulation of up to 40 mM. The two amino acid exchanges that were observed 
in IPMS of strain B018 in comparison to the wild-type sequence are located in the putative 
binding pocket for L-leucine formed by three amino acid residues, which were deduced from 
the crystal structure of the homologous IPMS of M. tuberculosis (Koon et al., 2004). The 
exchange of the corresponding residues in IPMS of Saccharomyces cerevisiae, which had 
been identified by analysis of 5,5,5-trifluoro-DL-leucine resistant mutants, led to a loss of 
feedback-inhibition (Cavalieri et al., 1999). Indeed, also the simultaneous exchange in the 
three corresponding residues of the corynebacterial protein abolished feedback-inhibition 
(IPMS_mod). IPMS of M. tuberculosis is a homodimer and each monomer consists of a 
catalytic domain that is connected to a regulatory domain including the L-leucine-binding 
pocket (Koon et al., 2004). Huisman et al. (2012) showed that the removal of the C-terminus 
(regulatory domain) of the mycobacterial protein disrupts the functional substrate binding. 
The truncated variant is able to bind KIV, but cannot catalyze the reaction between KIV and 
acetyl-CoA. Although the catalytic and regulatory parts of the protein represent separate 
domains, they obviously influence each other. Therefore, Huisman and co-workers assumed 
that the regulatory domain is crucial for ensuring protein dynamics to provide efficient 
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catalysis. The homologous IPMS of C.  glutamicum exists also as a homodimer (Pátek et al., 
1994) and, due to its sequence similarity, it can be assumed that it shares similar 
characteristics concerning its structure and reaction mechanism with the mycobacterial 
enzyme. IPMS from B018 exhibited exceptional kinetic characteristics since its activity was 
comparable to the wild-type enzyme, but its feedback-inhibition was completely lost. Similar 
mutations were identified in the aspartate kinase of C. glutamicum, resulting in enzyme 
activities comparable to the wild-type enzyme, but it was not inhibitable by L-lysine plus              
L-threonine (Chen et al., 2011). In contrast to IPMS_B018, the amino acid exchanges of 
IPMS_mod obviously negatively affect the enzymatic abilities of the catalytic domain. This 
suggests an influence of the regulatory domain on the catalytic domain as it was shown for 
the mycobacterial homolog.   
The most significant step to achieve high L-leucine productivity was to reach a high 
expression of leuA_B018. For the construction of a plasmid-free producer strain, the 
expression of leuA_B018 was increased by replacement of the native promoter and 
attenuation region with the strong tuf promoter and by integration of up to three copies of this 
Ptuf-leuA_B018 module into the C. glutamicum genome. A significant increase in expression 
of leuBCD was achieved by deletion of the transcriptional repressor LtbR (Brune et al., 2007) 
and contributed to increased L-leucine accumulation.   
 
4.2 Increasing precursor supply, detecting further limitations, and 
performing transcriptomics 
Acetohydroxyacid synthase (AHAS) was identified as key enzyme for the production of         
L-valine (Leyval et al., 2003) because its overexpression or the abolishment of its feedback-
inhibition mechanism leads to increased L-valine production (section 1.4). Like many other 
enzymes that represent the starting point of a specific biosynthesis pathway, this enzyme is 
inhibited by its end-products, in this case the three BCAAs (Eggeling et al., 1987). Since its 
inhibition does not exceed 57%, this enzyme is not as tightly inhibited as IPMS and is still 
enzymatically active even in the presence of high BCAA concentrations so that L-leucine 
formation is not prevented. Nevertheless, preventing the feedback inhibition of AHAS by 
mutating its ilvN-encoded regulatory subunit (Elišáková et al., 2005) resulted in increased 
precursor supply and L-leucine accumulation. This step also led to an increase of the               
by-product L-valine that had to be addressed. The reduction of by-product formation is a 
crucial factor in strain design and was also a focus of this work because large accumulation 
of by-products decreases the product yield and increases the costs of purification and 
recovery of the desired compound (Park et al., 2008). Reduction of L-valine formation was 
mainly achieved by increasing the activity of feedback-resistant IPMS using multiple copies 
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of the construct Ptuf-leuA_B018 to redirect KIV to L-leucine formation instead of L-valine 
synthesis. Remarkably, the integration of leuA_B018 under control of the tuf promoter 
yielded higher L-leucine concentrations (55 mM) in a strain with deleted ltbR and feedback-
resistant AHAS than plasmid-based overexpression of leuA_B018 in the same strain 
background (45 mM), although IPMS activity was about 3-4-fold higher with the latter 
approach. There are reports in literature that a moderate expression of genes can be more 
beneficial than plasmid-based overexpression because the latter can, for example, lead to 
non-physiologically high accumulation of intermediates, which can have toxic and detrimental 
effects (Reinscheid et al., 1994).  
Plasmid-based expression in MV-Leu55 of leuCD, leuB and ilvE revealed no further 
limitations in the respective enzymatic activities. Besides that, the transport systems for           
L-leucine were also addressed. Neither plasmid-based expression of brnFE nor the deletion 
of brnQ yielded higher product concentrations. The activation of brnFE expression encoding 
the exporter of the BCAAs and L-methionine was previously shown to occur upon increased 
cytoplasmic concentrations of these amino acids via the transcriptional activator Lrp 
(Kennerknecht et al., 2002; Lange et al., 2012; Mustafi et al., 2012) and was obviously 
sufficient for effective L-leucine export. Furthermore, L-leucine is not lost from the 
supernatant by re-uptake via the brnQ-encoded importer. In contrast, overexpression of 
brnFE and deletion of brnQ was beneficial for the production of L-isoleucine (Xie et al., 2012). 
Genome-wide expression analysis verified increased expression of genes responsible for 
L-leucine biosynthesis and proved the success of the metabolic engineering steps performed. 
Increased expression of leuCD/leuB and brnFE was attributed to the deletion of ltbR and 
activation via Lrp due to increased internal BCAA concentrations, respectively (see above).  
Additionally, cg3022 appeared as the highest up-regulated gene when L-leucine was 
produced. The Cg3022 protein is annotated as an putative acetyl-CoA acetyltransferase and 
shares significant sequence similarity to the C-terminal regulatory domain of IPMS. Deletion 
of cg3022 had no influence on L-leucine biosynthesis, but led to higher L-valine accumulation 
of the respective strain (MV-Leu55 Δcg3022), which could be a hint for Cg3022 being 
connected to L-valine biosynthesis or its regulation. Further investigations are necessary to 
unravel the function of Cg3022. It may represent a novel target for optimization of L-valine 
biosynthesis. This employed DNA microarray-based strategy represents a useful tool to 
identify novel target genes and was already used for improving L-lysine production with 
C. glutamicum by Sindelar and Wendisch (2007).  
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4.3 Balancing titer, yield, and productivity 
The production of L-leucine is performed in a growth-coupled process. The biosynthesis of 
the BCAAs is closely connected to the central metabolism by using pyruvate as a substrate 
so that both biomass and product formation influence the overall productivity. That means 
that the flux of the glucose-derived precursor pyruvate splits up into biomass and product, 
therby preventing the simultaneous maximization of growth yield and product yield (Zhuang 
et al., 2013). Due to the high metabolic costs of two molecules of pyruvate and one molecule 
of acetyl-CoA for the synthesis of one molecule of L-leucine, growth rates significantly 
decrease with increased product concentrations (section 3.8). Reports dealing with the 
modeling of bioprocesses to achieve optimal results (Anesiadis et al., 2008; Zhuang et al., 
2013) came to the conclusion that the three factors yield, productivity, and product titer have 
to be balanced and that this balance is crucial to design an economically viable process. 
High titer is especially required to reach high product concentrations and for minimizing the 
costs of separation of product and by-product (Zhuang et al., 2013). High yields from carbon 
sources (glucose in this work) are desired to achieve as much product as possible from small 
substrate amounts to reduce costs for feedstock used for fermentation. Also reduced process 
times for an economic process have to be addressed, which is reflected in high volumetric 
productivity. Summed up, the goal is to achieve high product titers in a short period of time 
with high yields to reduce capital as well as operating costs and to facilitate downstream 
processing. First steps in strain construction in this work aimed at reaching high product titers 
and yields. Strain MV-Leu55 reached the highest L-leucine titer (55 mM) and yield (0.25 mol 
per mol glucose) in shake flask experiments, but exhibited a decreasing growth rate after 
10 h accompanied by a decreased glucose uptake rate. This led to a rather low volumetric 
productivity. The assumption that the reduced growth rate might be caused by high L-leucine 
concentrations could not be confirmed. Lange (2004) showed that L-leucine has only a 
moderate negative effect on the growth rate even at concentrations of about 100 mM. 
Besides that, MV-Leu55 was the only strain that exhibited a bi-phasic growth behavior. The 
reason for this is unclear. Interestingly, a growth behavior similar to that of MV-Leu55 has 
recently been reported for a KIV producer of C. glutamicum (Buchholz et al., 2013). Another 
notable observation was that this bi-phasic growth did not appear in batch fermentations. It is 
possible that this effect is due to the constant aeration of the fermentation vessel, which 
provides sufficient oxygen supply preventing the culture to become anaerobic. However, this 
does not explain why only MV-Leu55 exhibited bi-phasic growth in shake flask cultivation. 
Possibly, the high L-leucine production load makes the strain more sensitive to the limited 
aeration as characteristic for shake flask cultivation. It was reported by Varma and Palsson 
(1994) that appropriate control of oxygen supply can enhance population stability of 
engineered L-valine, L-tryptophan, and L-lysine production strains.  
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The glucose uptake rate of strain MV-Leu55 could be increased by 40% by deletion of the 
iolR gene, which leads to the derepression of iolT1 encoding a myo-inositol transporter which 
also catalyzes glucose uptake (Ikeda et al. 2011, Klaffl et al. 2013; Lindner et al. 2011). 
Glucose imported by IolT1 is phosphorylated by an ATP-dependent glucokinase (glk, 
cg2399; Park et al. 2000) or by a polyphosphate/ATP-dependent glucokinase (ppgK, cg2091; 
Lindner et al. 2010) and channeled into central metabolism. Deletion of iolR in MV-Leu55 
resulted in a slightly increased and constant growth rate that led to a shortened cultivation 
time and a 40% increase of volumetric productivity. Surprisingly, the introduction of the third 
Ptuf-leuA_B018 copy, which failed in strain MV-Leu55, was easily achieved in strain          
MV-Leu55 ΔiolR. The reason for this difference is not known. It might be related to the 
presence of the PTS-independent glucose uptake system IolT1, but other IolR target genes 
that are derepressed could also play a role. Interestingly, Ikeda (2012) obtained data 
indicating that the employment of a non-PTS-dependent glucose transport system or co-
utilization of the PTS and the non-PTS route for glucose uptake, as it is the case for          
MV-Leu55 ΔiolR, could increase cell robustness in large-scale industrial fermentation 
processes.  
Strain MV-LeuF1, which carries three Ptuf-leuA_B018 copies, produced significant 
concentrations of L-valine, which could be diminished by increasing the supply of acetyl-CoA 
by reduction of citrate synthase expression via a promoter exchange (van Ooyen et al., 
2012). The resulting strain MV-LeuF2 exhibited the highest volumetric productivity so far. 
These results demonstrate that a balanced precursor supply and moderate increase of 
enzyme activities is a very efficient way to redirect the metabolic flux at important branch 
points. 
 
4.4 Fed-batch fermentations  
In fed-batch cultivations, a pH of 6.5 turned out to be favorable for the production of L-leucine 
with strains MV-LeuF1 and MV-Leu2. Growth rates of MV-LeuF1 at pH 6.5 and 7.2 were 
similar, which is in line with the findings of Follmann and colleagues (2009) that effective pH 
homeostasis in C. glutamicum takes place between pH values from 6 to 9. Interestingly,      
MV-LeuF1 stopped growing at an OD600 of 5-6 when cultivated at pH 8.0. One possible 
explanation is a detrimental internal accumulation of amino acids due to a preferential uptake 
of BCCAs in comparison to excretion. The optimum pH for the uptake of L-isoleucine was 
reported to be 8.5 (Ebbighausen et al., 1989). Nevertheless, as data for the pH optima for 
uptake and excretion of L-valine and L-leucine are lacking, further investigation is necessary 
to explain the effect of the pH value on the L-leucine production process.  
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Despite increased L-lysine concentrations, an important advantage of pH 6.5 was a 
reduction of the by-products L-valine and L-alanine. Since L-leucine, L-valine, and L-alanine 
share almost the same isoelectric point, the industrial recovery process becomes very 
difficult when the latter two amino acids accumulate to high amounts (Hou et al., 2012). 
Consequently, both strain design as well as fermentation process performance contribute to 
by-product minimization. 
Using optimized cultivation conditions in the bioreactor, a balance of the three crucial 
factors titer, yield, and productivity was achieved. The highest molar product yield of 0.3 mol 
L-leucine per mol of glucose was obtained with strain MV-LeuF2. This corresponds to 50% of 
the theoretical maximal yield (calculated to be 60%) with non-growing cells of C. glutamicum. 
MV-LeuF2 exhibited a maximal growth rate of 0.2 h-1, which is about 50% of the growth rate 
of the wild type under identical conditions. The maximum volumetric productivity in the feed 
phase was 4.3 mmol l-1 h-1 and maximal L-leucine titers exceeded 180 mM. Values were 
calculated up to the point where precipitation of L-leucine was observed because only the 
soluble L-leucine fraction was taken into account for calculating yield and volumetric 
productivity. Precipitation of L-leucine above approximately 150 mM has two benefits: firstly, 
it simplifies downstream processing and, secondly, an insoluble product has no osmotic 
effect on the cells, which is helpful to prolong the fermentation process. Strain MV-LeuF2 
achieved a balance of titer, yield, and productivity and reached the highest values for these 
three factors reported so far for a bacterial L-leucine production strain cultivated in a defined 
minimal medium. Besides that, MV-LeuF2 is prototrophic, genetically defined, and does not 
carry plasmids. All these aspects make it highly interesting for industrial application. In 
contrast, previously described L-leucine-production strains of C. glutamicum were generated 
by random mutagenesis and contained amino acid auxotrophies. Although these strains 
reach comparable L-leucine titers (>20 g l-1), their cultivation requires the addition of the 
corresponding amino acids to the cultivation medium, which increases the production costs 
(Ambe-Ono et al., 1996). As already mentioned, there are only few works dealing with          
L-leucine production and even no report about a rationally designed C. glutamicum strain. 
Only E. coli strains were engineered rationally for L-leucine production, but they did not reach 
performances comparable to the strains in this work (Park and Lee, 2010). In contrast, 
several reports concerning L-valine and L-isoleucine production using C. glutamicum are 
described and selected production values are given in the following.  
L-Valine titers of 410 mM with maximum yields of 0.75 to 0.86 mol per mol of glucose 
were reported for aerobic fed-batch fermentations at high cell densities (Blombach et al., 
2008) and 1280 mM with yields up to 0.88 mol per mol glucose were obtained under oxygen-
deprived conditions (Hasegawa et al., 2013). Based on a theoretical yield of 1 mol per mol of 
glucose, these values demonstrate the availability of high-performance C. glutamicum 
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production strains for this BCAA. Also a variety of L-isoleucine producers exist. Considering a 
maximal theoretical yield of 0.78 mol of L-isoleucine per mol glucose, titers up to                
234 mM L-isoleucine with a yield of 0.165 mol per mol of glucose (Yin et al., 2012) are 
comparably low. Despite the fact that a direct comparison of the BCAA production strains is 
not possible due to different factors such as process design, theoretical yields, and solubility, 
values reached with the L-leucine production strains created in this work are satisfying, but 
can be certainly improved. A great advantage of rationally designed strains is the possibility 
to optimize them further in comparison to strains obtained by random mutagenesis, which 
often result in “dead-end” strains (section 1.4). Possible improvements of L-leucine 
production are discussed in section 4.6. 
. 
4.5 Production of 2-ketoiscocaproate 
The keto acid 2-ketoisocaproate (KIC), the direct precursor of L-leucine, represents an 
interesting commercial product due to its applications in different fields (section 1.2). Since it 
is mainly produced chemically, the biotechnological production is an interesting alternative. In 
this work, it was shown that KIC production strains can easily be achieved by deleting ilvE in 
existing L-leucine producers. The gene ilvE codes for the enzyme IlvE, which is the main 
transaminase for the conversion of the keto acids KIC, KIV, and KMV into L-leucine, L-valine, 
and L-isoleucine, respectively, in an L-glutamate dependent manner (Radmacher et al., 
2002). IlvE has rather high affinities for its three substrates, with KM values of 0.15 mM, 
0.63 mM, and 0.23 mM for KIC, KIV, and KMV, respectively (Marienhagen et al., 2005). 
Correspondingly, the deletion of ilvE leads to auxotrophies for L-leucine and L-isoleucine in 
the wild-type strain, but not for L-valine because transaminase AvtA exhibits high activity and 
affinity (KM = 2.51 mM) for the formation of L-valine from KIV in an L-alanine dependent 
manner (Marienhagen et al., 2005). Besides that, other aminotransferases such as AroT 
have weak side activities for L-leucine formation. This is also true for AvtA exhibiting a rather 
weak affinity for KIC, with a KM value of 16.84 mM (Marienhagen et al., 2005). The 
C. glutamicum wild-type strain and also the ΔilvE strain do not accumulate KIC in the 
supernatant. Since IPMS is strongly feedback-inhibited, even small internal L-leucine 
concentrations due to the side activities of the other transaminases are sufficient to inhibit 
IPMS (section 4.1), preventing KIC to accumulate. Even in L-leucine producers, KIC was not 
detected in the supernatant, which confirms the effective transamination reaction performed 
by the ilvE-encoded transaminase. Correspondingly, transamination reaction by IlvE was not 
found to be a bottleneck for L-leucine production in this work. Only in fed-batch fermentations 
without feeding of additional ammonium sulfate, low KIC accumulation occurred, which offers 
the possibility to produce KIC by limiting the nitrogen concentration. 
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This work shows that L-leucine production strains can serve as a basis for the production 
of KIC. Recently, also Haas (2013) confirmed that deletion of ilvE in L-leucine producers 
leads to KIC production and that KIC accumulates to concentrations similar to the L-leucine 
concentrations obtained with the respective ancestor strains. Since it was intended to design 
strains devoid of auxotrophies, deletion of ilvE was not desired. Therefore, reduction of IlvE 
activity by exchanging the ATG start codon was used to enable both growth and KIC 
accumulation. This approach was successful for the tested KIC producers, MV-KICF1 and 
SH-KIC20, but had the disadvantage of very low volumetric productivities for KIC. Besides 
that, this approach worked better for the weaker production strain SH-KIC20. This strain 
reached the expected KIC concentrations of about 20 mM, whereas MV-KICF1 only reached 
the expected maximal 45 mM KIC when L-isoleucine was added to the medium. Interestingly, 
addition of L-leucine was neither necessary for SH-KIC20 nor for MV-KICF1. L-Leucine was 
still detected in significant concentrations as by-product. This observation was also found by 
Haas (2013) for other KIC producing strains. This can be explained by the fact that KIC 
accumulates to high internal KIC concentrations so that they reach the KM values of other 
transaminases which are able to convert KIC to L-leucine as side activity (see above). 
Eventually, growth and even accumulation of L-leucine is enabled due to the high KIC 
concentrations. Since supplementation of L-isoleucine to MV-LeuF1 resulted in similar growth 
and productivity as its ancestor strain MV-LeuF1, it was confirmed that only L-isoleucine 
supplementation was necessary for enabling high growth rates.  
The start codon exchange was a proof-of-principle approach and showed that 
downregulation of IlvE activity allows a balance of growth and KIC accumulation without 
supplementation of BCAAs. To achieve higher productivities, other possibilities are 
conceivable. Gene expression of ilvE could be fine-tuned by using different promoter libraries 
(Hammer et al., 2006). For example, different variants of dapA promoters described by 
Vašicová et al. (1999) could be employed. These were used for downregulating gltA 
expression by van Ooyen et al. (2012) and this strategy was also used for the construction of 
L-leucine production strain MV-LeuF2 in this work. Analogously to the optimization of 
fermentations of L-leucine production strains, process conditions for cultivation of KIC 
producers in bioreactors should be improved to reach the higher KIC titers obtained in shake 
flask cultivation. This could be done, for example, by testing different oxygen and pH 
conditions. Since the latter worked for L-leucine production to reduce by-product formation, 
optimization of process conditions should also be a possibility to decrease accumulation of 
the other keto acids KIV and KMV as well as L-leucine in favor of increased KIC production. 
Moreover, it is obviously important to finish fermentations at the point of highest KIC 
concentrations to prevent a loss of KIC from the supernatant. It is likely that this was caused 
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due to re-uptake of KIC by the cells and subsequent transamination to L-leucine as it was 
already shown by Groeger and Sahm (1987). 
Very recently, Bückle-Vallant et al. (2014) published a C. glutamicum strain for the 
production of KIC. The reported strain carried a plasmid and was not designed on the basis 
of plasmid-free L-leucine producers as shown in this work (section 1.4). With glucose as the 
sole carbon source, the strain reported by Bückle-Vallant reached KIC titers (54 ± 4 mM) and 
yields (0.22 mol per mol of glucose) in a comparable range as it was achieved with strain 
MV-KICF1 when supplemented with L-isoleucine (Table 12). 
In contrast to the reported KIV producers reported by Krause et al. (2010) and Buchholz et 
al. (2013), with titers of approximately 188 mM and 303 mM KIV, respectively, KIC titers 
shown in this work and that of Bückle-Vallant and co-workers (2014) are rather low. 
Interestingly, only KIC concentrations up to approximately 50 mM were reached when 
additional glucose was fed at the end of the batch fermentations with strain MV-KICF1. 
Besides that, glucose was not fully consumed and cells stopped growing, leading to the 
assumption that cell growth was inhibited by the elevated KIC concentrations. Bückle-Vallant 
et al. (2014) indeed found competitive and noncompetitive inhibition of IPMS and IPMD, 
respectively, by KIC, which provides an explanation of the observed limited KIC production 
capacities. Also a competitive inhibition of AHAS by KIV was reported by Krause et al. (2010) 
so that the formation of this keto acid as by-product should be minimized. Therefore, the 
inhibition mechanisms should be addressed in future work to improve KIC production.   
 
4.6 Outlook: Possible improvements for L-leucine and 2-ketoisocaproate 
production 
Besides the performed metabolic engineering steps and optimized process conditions, 
further aspects should be considered to improve L-leucine production and that of KIC as well. 
Apart from the pH value, oxygen supply is another parameter that can be addressed to 
improve strain performance. For example, Hou et al. (2012) showed that by-product 
formation in L-valine production with C. glutamicum can be reduced by different dissolved 
oxygen concentrations. Similarly, Akashi et al. (1978) reported that L-leucine accumulation 
can be increased under oxygen-limited conditions. Another possibility would be to cultivate 
the engineered cells anaerobically to reduce growth but retain metabolic activity. Hasegawa 
et al. (2013) engineered strains that exhibit high performance concerning titer, productivity, 
and yield for L-valine formation under oxygen-deprived conditions. Since NADPH is needed 
as co-factor for L-leucine biosynthesis (Figure 7), the improvement of NADPH supply, for 
example by overexpression of NAD kinases (Shi et al., 2012), should also be beneficial for   
L-leucine production. The downregulation of ilvA expression coding for threonine 
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dehydratase could also be beneficial for L-leucine formation because it would reduce the 
competition of L-isoleucine and L-valine/L-leucine intermediates for the enzymes AHAS, 
AHAIR, and DHAD (Holátko et al., 2009) (Figure 7). Moreover, an L-isoleucine shortage 
caused by ilvA downregulation could derepress the attenuation of the ilvBNC operon 
(Morbach et al., 2000) or reduce the growth rate in favor of improved L-leucine formation as it 
was shown for L-valine production (Ruklisha et al., 2007). Another possibility to increase           
L-leucine production would be the exchange of the promoter of the ilvBNC operon including 
its attenuator sequence against a strong promoter to further increase precursor supply. 
All metabolic engineering steps of this work were performed rationally, but were mainly 
applied to local target genes. Another advanced approach for strain design represents 
systems metabolic engineering (Figure 13). This strategy provides a system-wide view of the 
producer cell and has already applied for C. glutamicum (Park et al., 2008, Wendisch et al., 
2006b). This strategy could be used to improve the existing L-leucine producers by, for 
example,  performing analysis of metabolic fluxes or proteomics. A first step towards this 
strategy was already done in this work by performing genome-wide expression analysis 
(transcriptomics) with different L-leucine producers that revealed a possible novel target gene 
(cg3022). 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 13. Systems metabolic engineering for advanced strain development (from 
Park and Lee, 2008).                                                                                                                                                 
Systems metabolic engineering represents an advancement of random 
mutagenesis/selection and targeted metabolic engineering. In this approach, systems-level 
analyses of data obtained by “omics”-technologies (i.e. genome, transcriptome, proteome, 
metabolome, and fluxome data) and computational analyses are combined with metabolic 
engineering. Fermentation and downstream processing are considered at early stages of 
strain design and performed to characterize the engineered strain and to improve it further. 
The systems metabolic engineering cycle is repeated until a strain with the desired properties 
is obtained. 
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Strains MV-LeuF1 and MV-LeuF2 might not only be highly interesting for industrial           
L-leucine production but additionally for the production of related products. This was shown 
for the production of KIC in this work. Moreover, similar to the production of isobutanol from 
KIC (Blombach et al., 2011), the production of isopentanol should be possible from 
KIC (Cann and Liao, 2010). 
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